|
Utah
|
87-0327982
|
(State or other jurisdiction of
|
(IRS Employer
|
incorporation or organization)
|
Identification No.)
|
Large accelerated filer
o
|
Accelerated filer
x
|
|
|
Non-accelerated filer
o
|
Smaller reporting company
o
|
(Do not check if a smaller reporting company)
|
Emerging growth Company
o
|
|
|
|
|
|
|
|
|
|
|
|||
|
|||
|
|||
|
|||
|
|||
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|||
|
|||
|
|||
|
|||
|
|||
|
|||
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|||
|
|||
|
|||
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
|
|
|
•
|
changes in laws and regulations, or their interpretation, applicable to direct selling or the nutritional supplement industry may prohibit or restrict the Company's ability to sell its products in some markets or require the Company to make changes to its business model in some markets;
|
•
|
extensive government regulations to which the Company's products, business practices and manufacturing activities are subject;
|
•
|
legal challenges to the Company's direct selling program or to the classification of its independent distributors;
|
•
|
effect of complex legal and regulatory requirements, particularly in China and South Korea;
|
•
|
impact of anti-bribery laws, including the U.S. Foreign Corrupt Practices Act;
|
•
|
its ability to attract and retain independent distributors;
|
•
|
the loss of one or more key independent distributors who have a significant sales network;
|
•
|
the full implementation of its joint venture for operations in China with Fosun Industrial Co., Ltd.;
|
•
|
registration of products for sale in China, or difficulty or increased cost of importing products into China;
|
•
|
cyber security threats and exposure to data loss;
|
•
|
reliance on information technology infrastructure;
|
•
|
the effect of fluctuating foreign exchange rates;
|
•
|
liabilities and obligations arising from improper activity by its independent distributors;
|
•
|
its relationship with, and its inability to control the actions of, its independent distributors, and other third parties with whom it does business;
|
•
|
changes to its independent distributor compensation plans;
|
•
|
geopolitical issues and conflicts;
|
•
|
negative consequences resulting from difficult economic conditions, including the availability of liquidity or the willingness of its customers to purchase products;
|
•
|
risks associated with the manufacturing of the Company's products;
|
•
|
uncertainties relating to the application of transfer pricing, duties, value-added taxes, and other tax regulations, and changes thereto;
|
•
|
changes in tax laws, treaties or regulations, or their interpretation, including the impact of the Tax Cuts and Jobs Act;
|
•
|
availability and integrity of raw materials;
|
•
|
the competitive nature of its business and the nutritional supplement industry;
|
•
|
negative publicity related to its products, ingredients, or direct selling organization and the nutritional supplement industry;
|
•
|
product liability claims;
|
•
|
the sufficiency of trademarks and other intellectual property rights; and
|
•
|
reliance on third-parties to distribute its products and provide support services to independent distributors.
|
Year Ended December 31,
|
|
2017
|
|
2016
|
|
2015
|
|||||||||||||||
NSP Americas:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
General health
|
|
$
|
74,492
|
|
|
44.9
|
%
|
|
$
|
78,187
|
|
|
44.4
|
%
|
|
$
|
80,315
|
|
|
44.8
|
%
|
Immune
|
|
20,451
|
|
|
12.3
|
|
|
19,185
|
|
|
10.9
|
|
|
22,042
|
|
|
12.3
|
|
|||
Cardiovascular
|
|
11,454
|
|
|
6.9
|
|
|
12,677
|
|
|
7.2
|
|
|
12,331
|
|
|
6.9
|
|
|||
Digestive
|
|
45,231
|
|
|
27.2
|
|
|
47,659
|
|
|
27.1
|
|
|
49,239
|
|
|
27.5
|
|
|||
Personal care
|
|
7,260
|
|
|
4.4
|
|
|
7,537
|
|
|
4.3
|
|
|
3,575
|
|
|
2.0
|
|
|||
Weight management
|
|
7,129
|
|
|
4.3
|
|
|
10,677
|
|
|
6.1
|
|
|
11,649
|
|
|
6.5
|
|
|||
Total NSP Americas
|
|
166,017
|
|
|
100.0
|
|
|
175,922
|
|
|
100.0
|
|
|
179,151
|
|
|
100.0
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
NSP Russia, Central and Eastern Europe:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
General health
|
|
$
|
14,813
|
|
|
46.0
|
%
|
|
$
|
12,907
|
|
|
43.0
|
%
|
|
$
|
13,332
|
|
|
42.4
|
%
|
Immune
|
|
3,530
|
|
|
11.0
|
|
|
3,349
|
|
|
11.2
|
|
|
3,853
|
|
|
12.2
|
|
|||
Cardiovascular
|
|
2,166
|
|
|
6.7
|
|
|
2,212
|
|
|
7.4
|
|
|
2,006
|
|
|
6.4
|
|
|||
Digestive
|
|
8,261
|
|
|
25.7
|
|
|
8,009
|
|
|
26.7
|
|
|
8,178
|
|
|
26.0
|
|
|||
Personal care
|
|
2,330
|
|
|
7.2
|
|
|
2,370
|
|
|
7.9
|
|
|
2,809
|
|
|
8.9
|
|
|||
Weight management
|
|
1,090
|
|
|
3.4
|
|
|
1,151
|
|
|
3.8
|
|
|
1,291
|
|
|
4.1
|
|
|||
Total NSP Russia, Central and Eastern Europe
|
|
32,190
|
|
|
100.0
|
|
|
29,998
|
|
|
100.0
|
|
|
31,469
|
|
|
100.0
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
Synergy WorldWide:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
General health
|
|
$
|
31,973
|
|
|
25.8
|
%
|
|
$
|
35,283
|
|
|
28.3
|
%
|
|
$
|
43,829
|
|
|
38.4
|
%
|
Immune
|
|
508
|
|
|
0.4
|
|
|
620
|
|
|
0.5
|
|
|
752
|
|
|
0.7
|
|
|||
Cardiovascular
|
|
50,702
|
|
|
40.9
|
|
|
51,684
|
|
|
41.4
|
|
|
34,191
|
|
|
30.0
|
|
|||
Digestive
|
|
16,121
|
|
|
13.0
|
|
|
12,536
|
|
|
10.0
|
|
|
17,746
|
|
|
15.6
|
|
|||
Personal care
|
|
8,532
|
|
|
6.9
|
|
|
8,981
|
|
|
7.2
|
|
|
5,697
|
|
|
5.0
|
|
|||
Weight management
|
|
15,997
|
|
|
12.9
|
|
|
15,689
|
|
|
12.6
|
|
|
11,866
|
|
|
10.4
|
|
|||
Total Synergy WorldWide
|
|
123,833
|
|
|
100.0
|
|
|
124,793
|
|
|
100.0
|
|
|
114,081
|
|
|
100.0
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
NSP China:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
General health
|
|
$
|
3,738
|
|
|
18.7
|
%
|
|
$
|
1,551
|
|
|
14.8
|
%
|
|
$
|
4
|
|
|
100.0
|
%
|
Immune
|
|
468
|
|
|
2.3
|
|
|
370
|
|
|
3.5
|
|
|
—
|
|
|
—
|
|
|||
Cardiovascular
|
|
3,886
|
|
|
19.4
|
|
|
2,617
|
|
|
25.1
|
|
|
—
|
|
|
—
|
|
|||
Digestive
|
|
8,361
|
|
|
41.8
|
|
|
4,323
|
|
|
41.4
|
|
|
—
|
|
|
—
|
|
|||
Personal care
|
|
350
|
|
|
1.8
|
|
|
629
|
|
|
6.0
|
|
|
—
|
|
|
—
|
|
|||
Weight management
|
|
3,186
|
|
|
15.9
|
|
|
956
|
|
|
9.2
|
|
|
—
|
|
|
—
|
|
|||
Total NSP China
|
|
19,989
|
|
|
100.0
|
|
|
10,446
|
|
|
100.0
|
|
|
4
|
|
|
100.0
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
Consolidated:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
General health
|
|
$
|
125,016
|
|
|
36.6
|
%
|
|
$
|
127,928
|
|
|
37.5
|
%
|
|
$
|
137,480
|
|
|
42.3
|
%
|
Immune
|
|
24,957
|
|
|
7.3
|
|
|
23,524
|
|
|
6.9
|
|
|
26,647
|
|
|
8.2
|
|
|||
Cardiovascular
|
|
68,208
|
|
|
19.9
|
|
|
69,190
|
|
|
20.3
|
|
|
48,528
|
|
|
14.9
|
|
|||
Digestive
|
|
77,974
|
|
|
22.8
|
|
|
72,527
|
|
|
21.3
|
|
|
75,163
|
|
|
23.1
|
|
|||
Personal care
|
|
18,472
|
|
|
5.4
|
|
|
19,517
|
|
|
5.7
|
|
|
12,081
|
|
|
3.7
|
|
|||
Weight management
|
|
27,402
|
|
|
8.0
|
|
|
28,473
|
|
|
8.3
|
|
|
24,806
|
|
|
7.6
|
|
|||
Total Consolidated
|
|
$
|
342,029
|
|
|
100.0
|
|
|
$
|
341,159
|
|
|
100.0
|
|
|
$
|
324,705
|
|
|
100.0
|
|
Category
|
|
Description
|
General health
|
|
The Company distributes a wide selection of general health products. The general health line is a combination of assorted health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision.
|
|
|
|
Immune
|
|
The Company distributes immune products. The immune line has been designed to offer products that support and strengthen the human immune system.
|
|
|
|
Cardiovascular
|
|
The Company distributes cardiovascular products. The cardiovascular line has been designed to offer products that combine a variety of superior heart health ingredients to give the cardiovascular system optimum support.
|
|
|
|
Digestive
|
|
The Company distributes digestive products. The digestive line has been designed to offer products that regulate intestinal and digestive functions in support of the human digestive system.
|
|
|
|
Personal care
|
|
The Company distributes a variety of personal care products for external use, including oils and lotions, aloe vera gel, herbal shampoo, herbal skin treatment, toothpaste and skin cleanser.
|
|
|
|
Weight management
|
|
The Company distributes a variety of weight management products. The weight management line has been designed to simplify the weight management process by providing healthy meal replacements and products that increase caloric burn rate.
|
|
|
2017
|
|
2016
|
|
2015
|
||||||||||||
|
|
Distributors
& Customers |
|
Managers
|
|
Distributors
& Customers |
|
Managers
|
|
Distributors
& Customers |
|
Managers
|
||||||
NSP Americas
|
|
236,200
|
|
|
5,600
|
|
|
269,100
|
|
|
6,400
|
|
|
286,600
|
|
|
6,500
|
|
NSP Russia, Central and Eastern Europe
|
|
138,300
|
|
|
3,200
|
|
|
140,600
|
|
|
2,800
|
|
|
163,200
|
|
|
2,800
|
|
Synergy WorldWide
|
|
107,300
|
|
|
4,200
|
|
|
123,000
|
|
|
3,700
|
|
|
126,400
|
|
|
3,400
|
|
Total
|
|
481,800
|
|
|
13,000
|
|
|
532,700
|
|
|
12,900
|
|
|
576,200
|
|
|
12,700
|
|
|
|
2017
|
|
2016
|
|
2015
|
||||||||||||
|
|
Distributors
& Customers |
|
Managers
|
|
Distributors
& Customers |
|
Managers
|
|
Distributors
& Customers |
|
Managers
|
||||||
NSP Americas
|
|
106,900
|
|
|
5,600
|
|
|
121,200
|
|
|
6,400
|
|
|
131,600
|
|
|
6,500
|
|
NSP Russia, Central and Eastern Europe
|
|
68,600
|
|
|
3,200
|
|
|
66,700
|
|
|
2,800
|
|
|
72,000
|
|
|
2,800
|
|
Synergy WorldWide
|
|
55,400
|
|
|
4,200
|
|
|
53,600
|
|
|
3,700
|
|
|
60,800
|
|
|
3,400
|
|
Total
|
|
230,900
|
|
|
13,000
|
|
|
241,500
|
|
|
12,900
|
|
|
264,400
|
|
|
12,700
|
|
|
|
2017
|
|
2016
|
|
2015
|
||||||||||||
|
|
Distributors
& Customers |
|
Managers
|
|
Distributors
& Customers |
|
Managers
|
|
Distributors
& Customers |
|
Managers
|
||||||
NSP Americas
|
|
83,300
|
|
|
2,100
|
|
|
116,900
|
|
|
3,200
|
|
|
127,900
|
|
|
3,000
|
|
NSP Russia, Central and Eastern Europe
|
|
40,600
|
|
|
700
|
|
|
44,900
|
|
|
600
|
|
|
47,000
|
|
|
700
|
|
Synergy WorldWide
|
|
63,500
|
|
|
2,900
|
|
|
72,000
|
|
|
3,000
|
|
|
76,600
|
|
|
2,300
|
|
Total
|
|
187,400
|
|
|
5,700
|
|
|
233,800
|
|
|
6,800
|
|
|
251,500
|
|
|
6,000
|
|
(Dollar amounts in thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
Year Ended December 31,
|
|
2017
|
|
2016
|
|
2015
|
|||||||||||||||
Net Sales:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
North America
|
|
$
|
151,380
|
|
|
44.2
|
%
|
|
$
|
168,883
|
|
|
49.5
|
%
|
|
$
|
171,486
|
|
|
52.8
|
%
|
Europe
|
|
55,719
|
|
|
16.3
|
|
|
50,299
|
|
|
14.7
|
|
|
53,237
|
|
|
16.4
|
|
|||
Asia Pacific
|
|
109,318
|
|
|
32.0
|
|
|
98,585
|
|
|
28.9
|
|
|
76,482
|
|
|
23.6
|
|
|||
Central & South America
|
|
25,612
|
|
|
7.5
|
|
|
23,392
|
|
|
6.9
|
|
|
23,500
|
|
|
7.2
|
|
|||
|
|
$
|
342,029
|
|
|
100.0
|
%
|
|
$
|
341,159
|
|
|
100.0
|
%
|
|
$
|
324,705
|
|
|
100.0
|
%
|
–
|
publicity regarding the Company, its products, its distribution channels or its competitors;
|
–
|
on-going motivation of the Company's independent distributors;
|
–
|
the public’s perceptions about the value and efficacy of the Company's products;
|
–
|
the public’s perceptions and acceptance of direct selling;
|
–
|
general and economic business conditions;
|
–
|
government regulations;
|
–
|
the Company's compensation arrangements, including any changes thereto, training and support for its independent distributors; and
|
–
|
competition in attracting and retaining independent distributors.
|
|
|
Market Prices
|
||||||
2017
|
|
High
|
|
Low
|
||||
First Quarter
|
|
$
|
14.48
|
|
|
$
|
8.80
|
|
Second Quarter
|
|
$
|
13.55
|
|
|
$
|
8.40
|
|
Third Quarter
|
|
$
|
13.20
|
|
|
$
|
9.35
|
|
Fourth Quarter
|
|
$
|
12.80
|
|
|
$
|
8.70
|
|
Plan category
|
|
Number of securities to
be issued upon exercise or
vesting of
outstanding options,
warrants and rights
|
|
Weighted average
exercise price of
outstanding options,
warrants and rights
|
|
Number of securities
remaining available for
issuance under equity
compensation plans
(excluding securities
reflected in column (a))
|
||||
|
|
(a)
|
|
(b)
|
|
(c)
|
||||
Equity compensation plans approved by security holders (1)
|
|
2,118,129
|
|
|
$
|
12.06
|
|
|
923,410
|
|
(1)
|
Consists of two plans: The Nature’s Sunshine Products, Inc. 2012 Stock Incentive Plan (the “2012 Incentive Plan”), and the Nature’s Sunshine Products, Inc. 2009 Stock Incentive Plan (the “2009 Incentive Plan”). The 2012 Incentive Plan was approved by the Company's shareholders on August 1, 2012, and an amendment to the 2012 Incentive Plan was approved by the Company's shareholders on January 14, 2015, to increase the number of shares available for issuance under the 2012 Incentive Plan by 1,500,000. The 2009 Incentive Plan was approved by the Company's shareholders on November 6, 2009. The terms of these plans are summarized in Note 11, “Capital Transactions”, of the Notes to Consolidated Financial Statements in Item 8, Part 2 of this report.
|
|
12/31/2012
|
|
12/31/2013
|
|
12/31/2014
|
|
12/31/2015
|
|
12/31/2016
|
|
12/31/2017
|
||||||||||||
Nature’s Sunshine Products, Inc.
|
$
|
100.00
|
|
|
$
|
132.97
|
|
|
$
|
128.68
|
|
|
$
|
90.73
|
|
|
$
|
139.18
|
|
|
$
|
108.24
|
|
NASDAQ Index
|
100.00
|
|
|
140.12
|
|
|
160.78
|
|
|
171.97
|
|
|
187.22
|
|
|
242.71
|
|
||||||
Peer Group
|
100.00
|
|
|
290.87
|
|
|
133.66
|
|
|
161.02
|
|
|
162.56
|
|
|
225.94
|
|
|
Year Ended December 31,
|
||||||||||||||||||
|
2017
|
|
2016
|
|
2015
|
|
2014
|
|
2013
|
||||||||||
Net sales
|
$
|
342,029
|
|
|
$
|
341,159
|
|
|
$
|
324,705
|
|
|
$
|
366,367
|
|
|
$
|
369,826
|
|
Cost of sales
|
(91,037
|
)
|
|
(90,937
|
)
|
|
(85,345
|
)
|
|
(91,584
|
)
|
|
(92,344
|
)
|
|||||
Gross profit
|
250,992
|
|
|
250,222
|
|
|
239,360
|
|
|
274,783
|
|
|
277,482
|
|
|||||
|
|
|
|
|
|
|
|
|
|
||||||||||
Operating expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Volume incentives
|
119,970
|
|
|
119,910
|
|
|
117,786
|
|
|
135,808
|
|
|
135,516
|
|
|||||
Selling, general and administrative
|
129,635
|
|
|
120,273
|
|
|
107,702
|
|
|
119,927
|
|
|
118,383
|
|
|||||
Operating income
|
1,387
|
|
|
10,039
|
|
|
13,872
|
|
|
19,048
|
|
|
23,583
|
|
|||||
Other income (expense), net
|
1,835
|
|
|
(773
|
)
|
|
(592
|
)
|
|
(34
|
)
|
|
1,993
|
|
|||||
Income before income taxes
|
3,222
|
|
|
9,266
|
|
|
13,280
|
|
|
19,014
|
|
|
25,576
|
|
|||||
Provision for income taxes
|
17,039
|
|
|
8,591
|
|
|
1,740
|
|
|
(743
|
)
|
|
7,923
|
|
|||||
Net income (loss) from continuing operations
|
(13,817
|
)
|
|
675
|
|
|
11,540
|
|
|
19,757
|
|
|
17,653
|
|
|||||
Income (loss) from discontinued operations
|
—
|
|
|
—
|
|
|
2,116
|
|
|
(9,957
|
)
|
|
(44
|
)
|
|||||
Net income (loss)
|
(13,817
|
)
|
|
675
|
|
|
13,656
|
|
|
9,800
|
|
|
17,609
|
|
|||||
Loss attributable to noncontrolling interests
|
(875
|
)
|
|
(1,464
|
)
|
|
(1,031
|
)
|
|
(219
|
)
|
|
—
|
|
|||||
Net income (loss) attributable to common shareholders
|
$
|
(12,942
|
)
|
|
$
|
2,139
|
|
|
$
|
14,687
|
|
|
$
|
10,019
|
|
|
$
|
17,609
|
|
|
December 31,
|
||||||||||||||||||
|
2017
|
|
2016
|
|
2015
|
|
2014
|
|
2013
|
||||||||||
Cash and cash equivalents
|
$
|
42,910
|
|
|
$
|
32,284
|
|
|
$
|
41,420
|
|
|
$
|
58,699
|
|
|
$
|
77,247
|
|
Working capital
|
48,852
|
|
|
31,466
|
|
|
48,382
|
|
|
63,340
|
|
|
80,025
|
|
|||||
Inventories
|
44,047
|
|
|
47,597
|
|
|
38,495
|
|
|
40,438
|
|
|
41,910
|
|
|||||
Property, plant and equipment, net
|
69,106
|
|
|
73,272
|
|
|
68,728
|
|
|
51,343
|
|
|
32,022
|
|
|||||
Total assets
|
195,195
|
|
|
205,570
|
|
|
200,520
|
|
|
196,799
|
|
|
199,612
|
|
|||||
Long-term liabilities
|
21,806
|
|
|
10,137
|
|
|
11,119
|
|
|
9,933
|
|
|
25,784
|
|
|||||
Total shareholders’ equity
|
119,732
|
|
|
132,398
|
|
|
136,265
|
|
|
128,957
|
|
|
105,259
|
|
|
Year Ended December 31,
|
||||||||||||||||||
|
2017
|
|
2016
|
|
2015
|
|
2014
|
|
2013
|
||||||||||
Operating activities
|
$
|
10,524
|
|
|
$
|
3,417
|
|
|
$
|
10,162
|
|
|
$
|
14,182
|
|
|
$
|
29,378
|
|
Investing activities
|
(3,204
|
)
|
|
(11,532
|
)
|
|
(18,592
|
)
|
|
(26,674
|
)
|
|
(8,564
|
)
|
|||||
Financing activities
|
1,573
|
|
|
(286
|
)
|
|
(7,578
|
)
|
|
(5,076
|
)
|
|
(21,331
|
)
|
|
Year Ended December 31,
|
||||||||||||||||||
|
2017
|
|
2016
|
|
2015
|
|
2014
|
|
2013
|
||||||||||
Cash dividends per share (1)
|
$
|
0.10
|
|
|
$
|
0.40
|
|
|
$
|
0.40
|
|
|
$
|
1.90
|
|
|
$
|
1.90
|
|
Basic and diluted earnings per share
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Basic weighted average number of shares
|
18,882
|
|
|
18,731
|
|
|
18,656
|
|
|
17,108
|
|
|
15,997
|
|
|||||
Diluted weighted average number of shares
|
18,882
|
|
|
19,056
|
|
|
19,177
|
|
|
17,641
|
|
|
16,390
|
|
|||||
Basic earnings (loss) per share attributable to common shareholders:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Net income (loss) from continuing operations
|
$
|
(0.69
|
)
|
|
$
|
0.11
|
|
|
$
|
0.67
|
|
|
$
|
1.15
|
|
|
$
|
1.10
|
|
Income (loss) from discontinued operations
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
0.11
|
|
|
$
|
(0.57
|
)
|
|
$
|
—
|
|
Net income (loss) attributable to common shareholders
|
$
|
(0.69
|
)
|
|
$
|
0.11
|
|
|
$
|
0.79
|
|
|
$
|
0.58
|
|
|
$
|
1.10
|
|
Diluted earnings (loss) per share attributable to common shareholders:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Net income (loss) from continuing operations
|
$
|
(0.69
|
)
|
|
$
|
0.11
|
|
|
$
|
0.66
|
|
|
$
|
1.12
|
|
|
$
|
1.08
|
|
Income (loss) from discontinued operations
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
0.11
|
|
|
$
|
(0.56
|
)
|
|
$
|
(0.01
|
)
|
Net income (loss) attributable to common shareholders
|
$
|
(0.69
|
)
|
|
$
|
0.11
|
|
|
$
|
0.77
|
|
|
$
|
0.56
|
|
|
$
|
1.07
|
|
|
December 31,
|
|||||||||||||
|
2017
|
|
2016
|
|
2015
|
|
2014
|
|
2013
|
|||||
Square footage of property in use
|
690,716
|
|
|
689,945
|
|
|
703,696
|
|
|
754,548
|
|
|
771,439
|
|
Number of employees
|
911
|
|
|
972
|
|
|
901
|
|
|
964
|
|
|
1,010
|
|
|
Net Sales by Operating Segment
|
||||||||||||||||
|
2017
|
|
2016
|
|
Percent
Change |
|
Impact of
Currency Exchange |
|
Percent
Change Excluding Impact of Currency |
||||||||
NSP Americas:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
NSP North America
|
$
|
140,405
|
|
|
$
|
148,048
|
|
|
(5.2
|
)%
|
|
$
|
213
|
|
|
(5.3
|
)%
|
NSP Latin America
|
25,612
|
|
|
27,874
|
|
|
(8.1
|
)%
|
|
(15
|
)
|
|
(8.1
|
)%
|
|||
|
166,017
|
|
|
175,922
|
|
|
(5.6
|
)%
|
|
198
|
|
|
(5.7
|
)%
|
|||
|
|
|
|
|
|
|
|
|
|
||||||||
NSP Russia, Central and Eastern Europe
|
32,190
|
|
|
29,998
|
|
|
7.3
|
%
|
|
197
|
|
|
6.7
|
%
|
|||
|
|
|
|
|
|
|
|
|
|
||||||||
Synergy WorldWide:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Synergy Asia Pacific
|
89,329
|
|
|
89,694
|
|
|
(0.4
|
)%
|
|
743
|
|
|
(1.2
|
)%
|
|||
Synergy Europe
|
23,529
|
|
|
24,328
|
|
|
(3.3
|
)%
|
|
455
|
|
|
(5.2
|
)%
|
|||
Synergy North America
|
10,975
|
|
|
10,771
|
|
|
1.9
|
%
|
|
—
|
|
|
1.9
|
%
|
|||
|
123,833
|
|
|
124,793
|
|
|
(0.8
|
)%
|
|
1,198
|
|
|
(1.7
|
)%
|
|||
|
|
|
|
|
|
|
|
|
|
||||||||
NSP China
|
19,989
|
|
|
10,446
|
|
|
91.4
|
%
|
|
—
|
|
|
91.4
|
%
|
|||
|
|
|
|
|
|
|
|
|
|
||||||||
|
$
|
342,029
|
|
|
$
|
341,159
|
|
|
0.3
|
%
|
|
$
|
1,593
|
|
|
(0.2
|
)%
|
•
|
$2.2 million of independent service fees paid to independent service providers in China;
|
•
|
$3.6 million of increased investment in China as the Company built its infrastructure; and
|
•
|
$3.6 million of increased depreciation related to Oracle as well as $1.8 million in other Oracle related costs.
|
(i)
|
Adjustments to valuation allowances increased the effective rate by
405.3 percent
in 2017. Included was the effect of an addition of valuation allowances on U.S. foreign tax credits, primarily resulting from the Tax Reform Act, as well as the impact of current year foreign losses that will not provide tax benefit.
|
(ii)
|
Adjustments relating to the U.S. tax impact of foreign operations increased the effective tax rate by
1.0 percent
in 2017. Included were adjustments for dividends received from foreign subsidiaries, adjustments for foreign tax credits, and foreign rate differentials.
|
(iii)
|
Cumulative unfavorable adjustments related to foreign operations increased the tax rate by
53.7 percent
in 2017. These adjustments relate to foreign items that are treated differently for tax purposes than they are for financial reporting purposes.
|
(iv)
|
Revaluation of deferred tax assets and liabilities to the lower U.S. federal tax rate caused by the enactment of the Tax Reform Act on December 22, 2017 increased the tax rate by
117.6 percent
in 2017.
|
(v)
|
Reduction of liabilities for unrecognized tax benefits related to the lapse of applicable statute of limitations decreased the tax rate by
91.1 percent
in 2017.
|
Components of U.S. tax impact of foreign operations
|
|
2017
|
|
2016
|
||
Dividends received from foreign subsidiaries
|
|
65.7
|
%
|
|
65.9
|
%
|
Foreign tax credits
|
|
(4.1
|
)
|
|
(91.8
|
)
|
Foreign tax rate differentials
|
|
(60.6
|
)
|
|
(27.1
|
)
|
Unremitted earnings
|
|
—
|
|
|
0.2
|
|
Other adjustments
|
|
—
|
|
|
(0.6
|
)
|
Total
|
|
1.0
|
%
|
|
(53.4
|
)%
|
|
Net Sales by Operating Segment
|
||||||||||||||||
|
2016
|
|
2015
|
|
Percent
Change |
|
Impact of
Currency Exchange |
|
Percent
Change Excluding Impact of Currency |
||||||||
NSP Americas:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
NSP North America
|
$
|
148,048
|
|
|
$
|
147,017
|
|
|
0.7
|
%
|
|
$
|
(404
|
)
|
|
1.0
|
%
|
NSP Latin America
|
27,874
|
|
|
32,134
|
|
|
(13.3
|
)%
|
|
(1,550
|
)
|
|
(8.4
|
)%
|
|||
|
175,922
|
|
|
179,151
|
|
|
(1.8
|
)%
|
|
(1,954
|
)
|
|
(0.7
|
)%
|
|||
|
|
|
|
|
|
|
|
|
|
||||||||
NSP Russia, Central and Eastern Europe
|
29,998
|
|
|
31,473
|
|
|
(4.7
|
)%
|
|
(163
|
)
|
|
(4.2
|
)%
|
|||
|
|
|
|
|
|
|
|
|
|
||||||||
Synergy WorldWide:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Synergy Asia Pacific
|
89,694
|
|
|
76,479
|
|
|
17.3
|
%
|
|
(229
|
)
|
|
17.6
|
%
|
|||
Synergy Europe
|
24,328
|
|
|
25,829
|
|
|
(5.8
|
)%
|
|
(68
|
)
|
|
(5.5
|
)%
|
|||
Synergy North America
|
10,771
|
|
|
11,773
|
|
|
(8.5
|
)%
|
|
—
|
|
|
(8.5
|
)%
|
|||
|
124,793
|
|
|
114,081
|
|
|
9.4
|
%
|
|
(297
|
)
|
|
9.7
|
%
|
|||
|
|
|
|
|
|
|
|
|
|
||||||||
NSP China
|
10,446
|
|
|
—
|
|
|
—
|
%
|
|
—
|
|
|
—
|
%
|
|||
|
|
|
|
|
|
|
|
|
|
||||||||
|
$
|
341,159
|
|
|
$
|
324,705
|
|
|
5.1
|
%
|
|
$
|
(2,414
|
)
|
|
5.8
|
%
|
•
|
$4.3 million of independent service fees, respectively, related to the Company's pre-opening product sales through Hong Kong;
|
•
|
$3.5 million of increased investment in China as the Company built its infrastructure;
|
•
|
$2.6 million of increased non-capitalizable internal labor costs related to the Oracle ERP implementation project; and
|
•
|
$2.1 million of increased employee health and other benefits.
|
•
|
A reduction of $3.3 million related to restructuring charges for the year ended December 31, 2015, that did not reoccur during the year ended December 31, 2016.
|
(i)
|
Adjustments to valuation allowances increased the effective rate by 77.6 percent in 2016. Included was the effect of an increase in valuation allowances on U.S. foreign tax credits, in addition to the impact of current year foreign losses that will not provide tax benefit.
|
(ii)
|
Cumulative unfavorable adjustments related to foreign operations increased the tax rate by 26.8 percent in 2016. These adjustments relate to foreign items that are treated differently for tax purposes than they are for financial reporting purposes.
|
(iii)
|
Adjustments relating to the U.S. tax impact of foreign operations decreased the effective tax rate by 53.4 percent in 2016. Included were adjustments for dividends received from foreign subsidiaries, adjustments for foreign tax credits, and foreign rate differentials.
|
Components of U.S. tax impact of foreign operations
|
|
2016
|
|
2015
|
||
Dividends received from foreign subsidiaries
|
|
65.9
|
%
|
|
5.4
|
%
|
Foreign tax credits
|
|
(91.8
|
)
|
|
(1.1
|
)
|
Foreign tax rate differentials
|
|
(27.1
|
)
|
|
(1.2
|
)
|
Unremitted earnings
|
|
0.2
|
|
|
(0.3
|
)
|
Other
|
|
(0.6
|
)
|
|
—
|
|
Total
|
|
(53.4
|
)%
|
|
2.8
|
%
|
|
For the Quarter Ended
|
||||||||||||||
|
March 31, 2017
|
|
June 30, 2017
|
|
September 30, 2017
|
|
December 31, 2017
|
||||||||
Net sales
|
$
|
83,098
|
|
|
$
|
81,344
|
|
|
$
|
89,301
|
|
|
$
|
88,286
|
|
Cost of sales
|
(21,728
|
)
|
|
(21,197
|
)
|
|
(23,505
|
)
|
|
(24,607
|
)
|
||||
Gross profit
|
61,370
|
|
|
60,147
|
|
|
65,796
|
|
|
63,679
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Volume incentives
|
28,983
|
|
|
28,288
|
|
|
30,716
|
|
|
31,983
|
|
||||
Selling, general and administrative
|
30,336
|
|
|
31,836
|
|
|
32,926
|
|
|
34,537
|
|
||||
Operating income (loss)
|
2,051
|
|
|
23
|
|
|
2,154
|
|
|
(2,841
|
)
|
||||
Other income (expense)
|
1,275
|
|
|
441
|
|
|
193
|
|
|
(74
|
)
|
||||
Income (loss) before income taxes
|
3,326
|
|
|
464
|
|
|
2,347
|
|
|
(2,915
|
)
|
||||
Provision (benefit) for income taxes
|
1,463
|
|
|
884
|
|
|
(1
|
)
|
|
14,693
|
|
||||
Net income (loss)
|
1,863
|
|
|
(420
|
)
|
|
2,348
|
|
|
(17,608
|
)
|
||||
Net loss attributable to noncontrolling interests
|
(297
|
)
|
|
(233
|
)
|
|
(95
|
)
|
|
(250
|
)
|
||||
Net income (loss) attributable to common shareholders
|
$
|
2,160
|
|
|
$
|
(187
|
)
|
|
$
|
2,443
|
|
|
$
|
(17,358
|
)
|
|
|
|
|
|
|
|
|
||||||||
Basic and diluted net income (loss) per common share:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Basic earnings (loss) per share attributable to common shareholders:
|
$
|
0.11
|
|
|
$
|
(0.01
|
)
|
|
$
|
0.13
|
|
|
$
|
(0.92
|
)
|
|
|
|
|
|
|
|
|
||||||||
Diluted earnings (loss) per share attributable to common shareholders:
|
$
|
0.11
|
|
|
$
|
(0.01
|
)
|
|
$
|
0.13
|
|
|
$
|
(0.92
|
)
|
|
|
|
|
|
|
|
|
||||||||
Dividends declared per common share
|
$
|
0.10
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
For the Quarter Ended
|
||||||||||||||
|
March 31, 2016
|
|
June 30, 2016
|
|
September 30, 2016
|
|
December 31, 2016
|
||||||||
Net sales
|
$
|
82,402
|
|
|
$
|
89,366
|
|
|
$
|
85,441
|
|
|
$
|
83,950
|
|
Cost of sales
|
(22,020
|
)
|
|
(23,078
|
)
|
|
(21,512
|
)
|
|
(24,327
|
)
|
||||
Gross profit
|
60,382
|
|
|
66,288
|
|
|
63,929
|
|
|
59,623
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Volume incentives
|
29,877
|
|
|
30,791
|
|
|
29,684
|
|
|
29,558
|
|
||||
Selling, general and administrative
|
28,385
|
|
|
31,249
|
|
|
29,187
|
|
|
31,452
|
|
||||
Operating income (loss)
|
2,120
|
|
|
4,248
|
|
|
5,058
|
|
|
(1,387
|
)
|
||||
Other income (expense), net
|
1,559
|
|
|
(622
|
)
|
|
20
|
|
|
(1,730
|
)
|
||||
Income (loss) before income taxes
|
3,679
|
|
|
3,626
|
|
|
5,078
|
|
|
(3,117
|
)
|
||||
Provision for income taxes
|
1,890
|
|
|
1,260
|
|
|
1,136
|
|
|
4,305
|
|
||||
Net income (loss)
|
1,789
|
|
|
2,366
|
|
|
3,942
|
|
|
(7,422
|
)
|
||||
Net loss attributable to noncontrolling interests
|
(280
|
)
|
|
(202
|
)
|
|
(213
|
)
|
|
(769
|
)
|
||||
Net income (loss) attributable to common shareholders
|
$
|
2,069
|
|
|
$
|
2,568
|
|
|
$
|
4,155
|
|
|
$
|
(6,653
|
)
|
|
|
|
|
|
|
|
|
||||||||
Basic and diluted net income (loss) per common share:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Basic earnings (loss) per share attributable to common shareholders:
|
$
|
0.11
|
|
|
$
|
0.14
|
|
|
$
|
0.22
|
|
|
$
|
(0.35
|
)
|
|
|
|
|
|
|
|
|
||||||||
Diluted earnings (loss) per share attributable to common shareholders:
|
$
|
0.11
|
|
|
$
|
0.14
|
|
|
$
|
0.22
|
|
|
$
|
(0.35
|
)
|
|
|
|
|
|
|
|
|
||||||||
Dividends declared per common share
|
$
|
0.10
|
|
|
$
|
0.10
|
|
|
$
|
0.10
|
|
|
$
|
0.10
|
|
|
Year Ended December 31,
|
||||||||||
|
2017
|
|
2016
|
|
2015
|
||||||
Operating activities
|
$
|
10,524
|
|
|
$
|
3,417
|
|
|
$
|
10,162
|
|
Investing activities
|
(3,204
|
)
|
|
(11,532
|
)
|
|
(18,592
|
)
|
|||
Financing activities
|
1,573
|
|
|
(286
|
)
|
|
(7,578
|
)
|
|
Total
|
|
Less than 1 year
|
|
1-3 years
|
|
3-5 years
|
|
After 5 years
|
||||||||||
Operating lease obligations
|
$
|
28,061
|
|
|
$
|
5,918
|
|
|
$
|
5,814
|
|
|
$
|
4,181
|
|
|
$
|
12,148
|
|
Self-insurance reserves (1)
|
593
|
|
|
593
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||
Other long-term liabilities reflected on the balance sheet (2)
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||
Unrecognized tax benefits (3)
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||
Revolving credit facility (4)
|
13,181
|
|
|
—
|
|
|
13,181
|
|
|
—
|
|
|
—
|
|
|||||
Other capital commitments (5)
|
1,720
|
|
|
1,720
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||
Total
|
$
|
43,555
|
|
|
$
|
8,231
|
|
|
$
|
18,995
|
|
|
$
|
4,181
|
|
|
$
|
12,148
|
|
(1)
|
At
December 31, 2017
, there were
$1.5 million
of liabilities. The Company retains a significant portion of the risks associated with certain employee medical benefits and product liability insurance. Recorded liabilities for self-insured risks are calculated using actuarial methods and are not discounted. Amounts for self-insurance obligations are included in accrued liabilities and long-term other liabilities on the Company’s consolidated balance sheet.
|
(2)
|
At
December 31, 2017
, there were
$2.0 million
of liabilities. The Company provides a nonqualified deferred compensation plan for its officers and certain key employees. Under this plan, participants may defer up to 100 percent of their annual salary and bonus (less the participant’s share of employment taxes). The deferrals become an obligation owed to the participant by the Company under the plan. Upon separation of the participant from the service of the Company, the obligation owed to the participant under the plan will be paid as a lump sum or over a period of either three or five years. As the Company cannot easily determine when its officers and key employees will separate from the Company, the Company is unable to estimate the years in which cash settlement may occur.
|
(3)
|
At
December 31, 2017
, there were
$4.6 million
of liabilities. Because of the high degree of uncertainty regarding the timing of future cash outflows associated with these liabilities, if any, the Company is unable to estimate the years in which cash settlement may occur with the respective tax authorities.
|
(4)
|
The Company entered into a revolving credit agreement with Bank of Americas, N.A., that permits the Company to borrow up to $25.0 million through July 11, 2020, bearing interest at LIBOR plus 1.25 percent. The Company must pay an annual commitment fee of 0.2 percent on the unused portion of the commitment. At
December 31, 2017
, the Company had
$11.8 million
available under this facility.
|
(5)
|
In
2017
, the Company made commitments of
$1.7 million
to purchase manufacturing equipment and leasehold improvements for its new headquarters in
2018
.
|
|
|
|
With Strengthening of U.S. Dollar by:
|
|||||||||||||||||||||
|
|
|
10%
|
|
15%
|
|
25%
|
|||||||||||||||||
|
|
|
($)
|
|
(%)
|
|
($)
|
|
(%)
|
|
($)
|
|
%)
|
|||||||||||
Net sales
|
$
|
342,029
|
|
|
$
|
(14,854
|
)
|
|
(4.3
|
)%
|
|
$
|
(21,312
|
)
|
|
(6.2
|
)%
|
|
$
|
(32,679
|
)
|
|
(9.6
|
)%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
Cost and expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Cost of sales
|
91,037
|
|
|
(4,710
|
)
|
|
(5.2
|
)%
|
|
(6,758
|
)
|
|
(7.4
|
)%
|
|
(10,362
|
)
|
|
(11.4
|
)%
|
||||
Volume incentives
|
119,970
|
|
|
(5,790
|
)
|
|
(4.8
|
)%
|
|
(8,308
|
)
|
|
(6.9
|
)%
|
|
(12,738
|
)
|
|
(10.6
|
)%
|
||||
Selling, general and administrative
|
129,635
|
|
|
(4,058
|
)
|
|
(3.1
|
)%
|
|
(5,822
|
)
|
|
(4.5
|
)%
|
|
(8,927
|
)
|
|
(6.9
|
)%
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
Operating income
|
$
|
1,387
|
|
|
$
|
(296
|
)
|
|
(21.3
|
)%
|
|
$
|
(424
|
)
|
|
(30.6
|
)%
|
|
$
|
(652
|
)
|
|
(47.0
|
)%
|
|
|
|
With Strengthening of U.S. Dollar by:
|
|||||||||||||||||||||
|
|
|
10%
|
|
15%
|
|
25%
|
|||||||||||||||||
|
|
|
(Loss) ($)
|
|
(Loss) (%)
|
|
(Loss) ($)
|
|
(Loss) (%)
|
|
(Loss) ($)
|
|
(Loss) (%)
|
|||||||||||
Financial Instruments Included in Current Assets Subject to Exchange Rate Risk
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Cash and cash equivalents
|
$
|
42,910
|
|
|
$
|
(2,445
|
)
|
|
(5.7
|
)%
|
|
$
|
(3,507
|
)
|
|
(8.2
|
)%
|
|
$
|
(5,378
|
)
|
|
(12.5
|
)%
|
Accounts receivable, net
|
8,888
|
|
|
(293
|
)
|
|
(3.3
|
)%
|
|
(420
|
)
|
|
(4.7
|
)%
|
|
(644
|
)
|
|
(7.2
|
)%
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
Financial Instruments Included in Current Liabilities Subject to Exchange Rate Risk
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Accounts payable
|
4,215
|
|
|
(58
|
)
|
|
(1.4
|
)%
|
|
(83
|
)
|
|
(2.0
|
)%
|
|
(127
|
)
|
|
(3.0
|
)%
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
Net Financial Instruments Subject to Exchange Rate Risk
|
$
|
47,583
|
|
|
$
|
(2,680
|
)
|
|
(5.6
|
)%
|
|
$
|
(3,844
|
)
|
|
(8.1
|
)%
|
|
$
|
(5,895
|
)
|
|
(12.4
|
)%
|
|
Translated into
U.S. Dollars |
|
At Spot Exchange Rate per
One U.S. Dollar |
|||
Cash and Cash Equivalents
|
|
|
|
|
|
|
South Korea (Won)
|
$
|
6,793
|
|
|
1,067.1
|
|
China (Yuan Renminbi)
|
5,304
|
|
|
6.5
|
|
|
Europe (Euro)
|
2,108
|
|
|
0.8
|
|
|
Japan (Yen)
|
2,080
|
|
|
112.7
|
|
|
Poland (Zloty)
|
1,255
|
|
|
3.5
|
|
|
Italy (Euro)
|
1,136
|
|
|
0.8
|
|
|
Canada (Dollar)
|
1,075
|
|
|
1.3
|
|
|
Malaysia
|
1,034
|
|
|
4.1
|
|
|
Other
|
6,105
|
|
|
Varies
|
|
|
Total foreign dominated cash and cash equivalents
|
$
|
26,890
|
|
|
|
|
U.S. dollars held by foreign subsidiaries
|
$
|
5,323
|
|
|
|
|
Total cash and cash equivalents held by foreign subsidiaries
|
$
|
32,213
|
|
|
|
|
Year ended December 31,
|
2017
|
|
2016
|
|
2015
|
|||
Canada (Dollar)
|
1.3
|
|
|
1.3
|
|
|
1.3
|
|
China (Yuan Renminbi)
|
6.5
|
|
|
7.0
|
|
|
6.5
|
|
European Markets (Euro)
|
0.8
|
|
|
0.9
|
|
|
0.9
|
|
Japan (Yen)
|
112.7
|
|
|
108.4
|
|
|
121.0
|
|
South Korea (Won)
|
1,067.0
|
|
|
1,160.9
|
|
|
1,132.5
|
|
Mexico (Peso)
|
19.7
|
|
|
18.6
|
|
|
15.8
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of December 31,
|
|
2017
|
|
2016
|
||||
Assets
|
|
|
|
|
|
|
||
Current assets:
|
|
|
|
|
|
|
||
Cash and cash equivalents
|
|
$
|
42,910
|
|
|
$
|
32,284
|
|
Accounts receivable, net of allowance for doubtful accounts of $395 and $205, respectively
|
|
8,888
|
|
|
7,738
|
|
||
Investments available for sale
|
|
—
|
|
|
1,776
|
|
||
Assets held for sale
|
|
998
|
|
|
521
|
|
||
Inventories
|
|
44,047
|
|
|
47,597
|
|
||
Prepaid expenses and other
|
|
5,666
|
|
|
4,585
|
|
||
Total current assets
|
|
102,509
|
|
|
94,501
|
|
||
Property, plant and equipment, net
|
|
69,106
|
|
|
73,272
|
|
||
Investment securities - trading
|
|
1,980
|
|
|
1,391
|
|
||
Intangible assets, net
|
|
709
|
|
|
976
|
|
||
Deferred income tax assets
|
|
8,283
|
|
|
21,590
|
|
||
Other assets
|
|
12,608
|
|
|
13,840
|
|
||
|
|
$
|
195,195
|
|
|
$
|
205,570
|
|
|
|
|
|
|
||||
Liabilities and Shareholders’ Equity
|
|
|
|
|
|
|
||
Current liabilities:
|
|
|
|
|
|
|
||
Accounts payable
|
|
$
|
4,215
|
|
|
$
|
5,305
|
|
Accrued volume incentives and service fees
|
|
18,774
|
|
|
16,264
|
|
||
Accrued liabilities
|
|
24,980
|
|
|
24,400
|
|
||
Deferred revenue
|
|
3,348
|
|
|
3,672
|
|
||
Revolving credit facility
|
|
—
|
|
|
9,919
|
|
||
Related party note
|
|
506
|
|
|
—
|
|
||
Income taxes payable
|
|
1,834
|
|
|
3,475
|
|
||
Total current liabilities
|
|
53,657
|
|
|
63,035
|
|
||
Liability related to unrecognized tax benefits
|
|
4,633
|
|
|
6,755
|
|
||
Long-term debt and revolving credit facility
|
|
13,181
|
|
|
—
|
|
||
Deferred compensation payable
|
|
1,980
|
|
|
1,391
|
|
||
Long-term deferred income tax liabilities
|
|
770
|
|
|
—
|
|
||
Other liabilities
|
|
1,242
|
|
|
1,991
|
|
||
Total liabilities
|
|
75,463
|
|
|
73,172
|
|
||
|
|
|
|
|
||||
Shareholders’ equity:
|
|
|
|
|
|
|
||
Common stock, no par value; 50,000 shares authorized, 18,919 and 18,757 shares issued and outstanding as of December 31, 2017, and 2016, respectively
|
|
131,525
|
|
|
129,654
|
|
||
Retained earnings (accumulated deficit)
|
|
(2,072
|
)
|
|
12,718
|
|
||
Noncontrolling interests
|
|
411
|
|
|
1,286
|
|
||
Accumulated other comprehensive loss
|
|
(10,132
|
)
|
|
(11,260
|
)
|
||
Total shareholders’ equity
|
|
119,732
|
|
|
132,398
|
|
||
|
|
$
|
195,195
|
|
|
$
|
205,570
|
|
Year Ended December 31,
|
|
2017
|
|
2016
|
|
2015
|
||||||
Net sales
|
|
$
|
342,029
|
|
|
$
|
341,159
|
|
|
$
|
324,705
|
|
Cost of sales
|
|
(91,037
|
)
|
|
(90,937
|
)
|
|
(85,345
|
)
|
|||
Gross profit
|
|
250,992
|
|
|
250,222
|
|
|
239,360
|
|
|||
|
|
|
|
|
|
|
||||||
Operating expenses:
|
|
|
|
|
|
|
|
|
|
|||
Volume incentives
|
|
119,970
|
|
|
119,910
|
|
|
117,786
|
|
|||
Selling, general and administrative
|
|
129,635
|
|
|
120,273
|
|
|
107,702
|
|
|||
Operating income
|
|
1,387
|
|
|
10,039
|
|
|
13,872
|
|
|||
Other income (expense):
|
|
|
|
|
|
|
|
|
|
|||
Interest and other income, net
|
|
144
|
|
|
591
|
|
|
1,486
|
|
|||
Interest expense
|
|
(289
|
)
|
|
(16
|
)
|
|
(130
|
)
|
|||
Foreign exchange gains (losses), net
|
|
1,980
|
|
|
(1,348
|
)
|
|
(1,948
|
)
|
|||
|
|
1,835
|
|
|
(773
|
)
|
|
(592
|
)
|
|||
Income from continuing operations before provision for income taxes
|
|
3,222
|
|
|
9,266
|
|
|
13,280
|
|
|||
Provision for income taxes
|
|
17,039
|
|
|
8,591
|
|
|
1,740
|
|
|||
Net income (loss) from continuing operations
|
|
(13,817
|
)
|
|
675
|
|
|
11,540
|
|
|||
Income from discontinued operations
|
|
—
|
|
|
—
|
|
|
2,116
|
|
|||
Net income (loss)
|
|
(13,817
|
)
|
|
675
|
|
|
13,656
|
|
|||
Net loss attributable to noncontrolling interests
|
|
(875
|
)
|
|
(1,464
|
)
|
|
(1,031
|
)
|
|||
Net income (loss) attributable to common shareholders
|
|
$
|
(12,942
|
)
|
|
$
|
2,139
|
|
|
$
|
14,687
|
|
|
|
|
|
|
|
|
||||||
Basic and diluted net income per common share
|
|
|
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
||||||
Basic earnings (loss) per share attributable to common shareholders:
|
|
|
|
|
|
|
|
|
|
|||
Net income (loss) from continuing operations
|
|
$
|
(0.69
|
)
|
|
$
|
0.11
|
|
|
$
|
0.67
|
|
Income from discontinued operations
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
0.11
|
|
Net income (loss) attributable to common shareholders
|
|
$
|
(0.69
|
)
|
|
$
|
0.11
|
|
|
$
|
0.79
|
|
|
|
|
|
|
|
|
||||||
Diluted earnings (loss) per share attributable to common shareholders:
|
|
|
|
|
|
|
|
|
|
|||
Net income (loss) from continuing operations
|
|
$
|
(0.69
|
)
|
|
$
|
0.11
|
|
|
$
|
0.66
|
|
Income from discontinued operations
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
0.11
|
|
Net income (loss) attributable to common shareholders
|
|
$
|
(0.69
|
)
|
|
$
|
0.11
|
|
|
$
|
0.77
|
|
|
|
|
|
|
|
|
||||||
Weighted average basic common shares outstanding
|
|
18,882
|
|
|
18,731
|
|
|
18,656
|
|
|||
Weighted average diluted common shares outstanding
|
|
18,882
|
|
|
19,056
|
|
|
19,177
|
|
|||
|
|
|
|
|
|
|
||||||
Dividends declared per common share
|
|
$
|
0.10
|
|
|
$
|
0.40
|
|
|
$
|
0.40
|
|
Year Ended December 31,
|
|
2017
|
|
2016
|
|
2015
|
||||||
Net income (loss)
|
|
$
|
(13,817
|
)
|
|
$
|
675
|
|
|
$
|
13,656
|
|
Foreign currency translation gain (loss) (net of tax)
|
|
1,113
|
|
|
(16
|
)
|
|
233
|
|
|||
Net unrealized gains (losses) on investment securities (net of tax)
|
|
15
|
|
|
(1
|
)
|
|
22
|
|
|||
Reclassification of net realized gains on marketable securities in net income (net of tax)
|
|
—
|
|
|
—
|
|
|
(294
|
)
|
|||
Total comprehensive income (loss)
|
|
(12,689
|
)
|
|
658
|
|
|
13,617
|
|
|||
Net loss attributable to noncontrolling interests
|
|
(875
|
)
|
|
(1,464
|
)
|
|
(1,031
|
)
|
|||
Total comprehensive income (loss) attributable to common shareholders
|
|
$
|
(11,814
|
)
|
|
$
|
2,122
|
|
|
$
|
14,648
|
|
|
Common Stock
|
|
Retained
Earnings (Accumulated deficit)
|
|
Noncontrolling
Interests
|
|
Accumulated
Other
Comprehensive
Income (Loss)
|
|
Total
|
|||||||||||||
|
Shares
|
|
Value
|
|
|
|
|
|||||||||||||||
Balance at January 1, 2015
|
18,662
|
|
|
$
|
125,489
|
|
|
$
|
10,891
|
|
|
$
|
3,781
|
|
|
$
|
(11,204
|
)
|
|
$
|
128,957
|
|
Share-based compensation expense
|
—
|
|
|
4,485
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
4,485
|
|
|||||
Tax deficiency from exercise of stock options
|
—
|
|
|
(520
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(520
|
)
|
|||||
Proceeds from the exercise of stock options
|
427
|
|
|
3,861
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
3,861
|
|
|||||
Repurchase of common stock
|
(501
|
)
|
|
(6,645
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(6,645
|
)
|
|||||
Cash dividends (0.40 per share)
|
—
|
|
|
—
|
|
|
(7,490
|
)
|
|
—
|
|
|
—
|
|
|
(7,490
|
)
|
|||||
Net income
|
—
|
|
|
—
|
|
|
14,687
|
|
|
(1,031
|
)
|
|
—
|
|
|
13,656
|
|
|||||
Other comprehensive loss
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(39
|
)
|
|
(39
|
)
|
|||||
Balance at December 31, 2015
|
18,588
|
|
|
126,670
|
|
|
18,088
|
|
|
2,750
|
|
|
(11,243
|
)
|
|
136,265
|
|
|||||
Share-based compensation expense
|
—
|
|
|
3,217
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
3,217
|
|
|||||
Tax deficiency from exercise of stock options
|
—
|
|
|
(233
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(233
|
)
|
|||||
Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax
|
169
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||
Cash dividends (0.40 per share)
|
—
|
|
|
—
|
|
|
(7,509
|
)
|
|
—
|
|
|
—
|
|
|
(7,509
|
)
|
|||||
Net income
|
—
|
|
|
—
|
|
|
2,139
|
|
|
(1,464
|
)
|
|
—
|
|
|
675
|
|
|||||
Other comprehensive loss
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(17
|
)
|
|
(17
|
)
|
|||||
Balance at December 31, 2016
|
18,757
|
|
|
129,654
|
|
|
12,718
|
|
|
1,286
|
|
|
(11,260
|
)
|
|
132,398
|
|
|||||
Share-based compensation expense
|
—
|
|
|
2,218
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
2,218
|
|
|||||
Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax
|
162
|
|
|
(347
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(347
|
)
|
|||||
Cash dividends (0.10 per share)
|
—
|
|
|
—
|
|
|
(1,848
|
)
|
|
—
|
|
|
—
|
|
|
(1,848
|
)
|
|||||
Net loss
|
—
|
|
|
—
|
|
|
(12,942
|
)
|
|
(875
|
)
|
|
—
|
|
|
(13,817
|
)
|
|||||
Other comprehensive income
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
1,128
|
|
|
1,128
|
|
|||||
Balance at December 31, 2017
|
18,919
|
|
|
$
|
131,525
|
|
|
$
|
(2,072
|
)
|
|
$
|
411
|
|
|
$
|
(10,132
|
)
|
|
$
|
119,732
|
|
Year Ended December 31,
|
|
2017
|
|
2016
|
|
2015
|
||||||
CASH FLOWS FROM OPERATING ACTIVITIES:
|
|
|
|
|
|
|
|
|
|
|||
Net income (loss)
|
|
$
|
(13,817
|
)
|
|
$
|
675
|
|
|
$
|
13,656
|
|
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
|
|
|
|
|
|
|
|
|
|
|||
Impairment of long-lived assets, net
|
|
113
|
|
|
221
|
|
|
—
|
|
|||
Provision for doubtful accounts
|
|
215
|
|
|
305
|
|
|
21
|
|
|||
Depreciation and amortization
|
|
8,634
|
|
|
4,808
|
|
|
4,525
|
|
|||
Share-based compensation expense
|
|
2,218
|
|
|
3,217
|
|
|
4,485
|
|
|||
(Gain) loss on sale of property and equipment
|
|
284
|
|
|
149
|
|
|
(2,703
|
)
|
|||
Deferred income taxes
|
|
14,134
|
|
|
766
|
|
|
(3,373
|
)
|
|||
Purchase of trading investment securities
|
|
(501
|
)
|
|
(429
|
)
|
|
(252
|
)
|
|||
Proceeds from sale of trading investment securities
|
|
151
|
|
|
147
|
|
|
239
|
|
|||
Realized and unrealized gains on investments
|
|
(216
|
)
|
|
(63
|
)
|
|
(470
|
)
|
|||
Foreign exchange losses (gains)
|
|
(1,980
|
)
|
|
1,348
|
|
|
1,948
|
|
|||
Changes in assets and liabilities:
|
|
|
|
|
|
|
|
|
|
|||
Accounts receivable
|
|
(1,241
|
)
|
|
(343
|
)
|
|
(1,091
|
)
|
|||
Inventories
|
|
5,177
|
|
|
(9,569
|
)
|
|
933
|
|
|||
Prepaid expenses and other
|
|
(1,191
|
)
|
|
2,442
|
|
|
636
|
|
|||
Other assets
|
|
2,391
|
|
|
(3,025
|
)
|
|
(4,010
|
)
|
|||
Accounts payable
|
|
(1,123
|
)
|
|
(935
|
)
|
|
593
|
|
|||
Accrued volume incentives and service fees
|
|
1,884
|
|
|
1,477
|
|
|
(1,427
|
)
|
|||
Accrued liabilities
|
|
(986
|
)
|
|
1,519
|
|
|
(3,451
|
)
|
|||
Deferred revenue
|
|
(324
|
)
|
|
(488
|
)
|
|
(557
|
)
|
|||
Income taxes payable
|
|
(1,758
|
)
|
|
1,924
|
|
|
(914
|
)
|
|||
Liability related to unrecognized tax positions
|
|
(2,129
|
)
|
|
(1,076
|
)
|
|
1,368
|
|
|||
Deferred compensation payable
|
|
589
|
|
|
347
|
|
|
6
|
|
|||
Net cash provided by operating activities
|
|
10,524
|
|
|
3,417
|
|
|
10,162
|
|
|||
CASH FLOWS FROM INVESTING ACTIVITIES:
|
|
|
|
|
|
|
|
|
|
|||
Purchases of property, plant and equipment
|
|
(5,501
|
)
|
|
(11,028
|
)
|
|
(22,527
|
)
|
|||
Proceeds from sale of property, plant and equipment
|
|
521
|
|
|
—
|
|
|
3,128
|
|
|||
Purchases of investments available for sale
|
|
—
|
|
|
—
|
|
|
(3
|
)
|
|||
Proceeds from sale/maturities of investments available for sale
|
|
1,776
|
|
|
5
|
|
|
810
|
|
|||
Purchase of intangible assets
|
|
—
|
|
|
(509
|
)
|
|
—
|
|
|||
Net cash used in investing activities
|
|
(3,204
|
)
|
|
(11,532
|
)
|
|
(18,592
|
)
|
|||
CASH FLOWS FROM FINANCING ACTIVITIES:
|
|
|
|
|
|
|
|
|
|
|||
Payments of cash dividends
|
|
(1,848
|
)
|
|
(7,509
|
)
|
|
(7,490
|
)
|
|||
Proceeds from new revolving credit facility
|
|
19,184
|
|
|
—
|
|
|
—
|
|
|||
Principal payments of new revolving credit facility
|
|
(6,003
|
)
|
|
—
|
|
|
—
|
|
|||
Net borrowings on original revolving credit facility
|
|
(9,919
|
)
|
|
7,223
|
|
|
2,696
|
|
|||
Related party note
|
|
506
|
|
|
|
|
|
|||||
Proceeds from exercise of stock options
|
|
(347
|
)
|
|
—
|
|
|
3,861
|
|
|||
Repurchase of common stock
|
|
—
|
|
|
—
|
|
|
(6,645
|
)
|
|||
Net cash provided by (used in) financing activities
|
|
1,573
|
|
|
(286
|
)
|
|
(7,578
|
)
|
|||
Effect of exchange rates on cash and cash equivalents
|
|
1,733
|
|
|
(735
|
)
|
|
(1,271
|
)
|
|||
Net increase (decrease) in cash and cash equivalents
|
|
10,626
|
|
|
(9,136
|
)
|
|
(17,279
|
)
|
|||
Cash and cash equivalents at beginning of the year
|
|
32,284
|
|
|
41,420
|
|
|
58,699
|
|
|||
Cash and cash equivalents at end of the year
|
|
$
|
42,910
|
|
|
$
|
32,284
|
|
|
$
|
41,420
|
|
Year Ended December 31,
|
|
2017
|
|
2016
|
|
2015
|
||||||
Supplemental disclosure of cash flow information:
|
|
|
|
|
|
|
|
|
|
|||
Cash paid for income taxes, net of refunds
|
|
$
|
4,597
|
|
|
$
|
3,589
|
|
|
$
|
9,782
|
|
Cash paid for interest
|
|
257
|
|
|
254
|
|
|
56
|
|
|||
Supplemental disclosure of noncash investing and financing activities:
|
|
|
|
|
|
|
|
|
|
|||
Purchases of property, plant and equipment included in accounts payable and accrued liabilities
|
|
$
|
63
|
|
|
$
|
178
|
|
|
$
|
1,081
|
|
|
2017
|
|
2016
|
|
2015
|
||||||
Net income (loss) attributable to common shareholders:
|
|
|
|
|
|
|
|
|
|||
Net income (loss) from continuing operations
|
$
|
(12,942
|
)
|
|
$
|
2,139
|
|
|
$
|
12,571
|
|
Income from discontinued operations
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
2,116
|
|
Net income (loss)
|
$
|
(12,942
|
)
|
|
$
|
2,139
|
|
|
$
|
14,687
|
|
|
|
|
|
|
|
||||||
Basic weighted-average shares outstanding
|
18,882
|
|
|
18,731
|
|
|
18,656
|
|
|||
|
|
|
|
|
|
||||||
Basic earnings (loss) per share attributable to common shareholders:
|
|
|
|
|
|
|
|
|
|||
Net income (loss) from continuing operations
|
$
|
(0.69
|
)
|
|
$
|
0.11
|
|
|
$
|
0.67
|
|
Income from discontinued operations
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
0.11
|
|
Net income (loss)
|
$
|
(0.69
|
)
|
|
$
|
0.11
|
|
|
$
|
0.79
|
|
|
|
|
|
|
|
||||||
Diluted Shares Outstanding
|
|
|
|
|
|
|
|
|
|||
Basic weighted-average shares outstanding
|
18,882
|
|
|
18,731
|
|
|
18,656
|
|
|||
Stock-based awards
|
—
|
|
|
325
|
|
|
521
|
|
|||
Diluted weighted-average shares outstanding
|
18,882
|
|
|
19,056
|
|
|
19,177
|
|
|||
|
|
|
|
|
|
||||||
Diluted earnings (loss) per share attributable to common shareholders:
|
|
|
|
|
|
|
|
|
|||
Net income (loss) from continuing operations
|
$
|
(0.69
|
)
|
|
$
|
0.11
|
|
|
$
|
0.66
|
|
Income from discontinued operations
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
0.11
|
|
Net income (loss)
|
$
|
(0.69
|
)
|
|
$
|
0.11
|
|
|
$
|
0.77
|
|
|
|
|
|
|
|
||||||
Potentially dilutive shares excluded from diluted-per-share amounts:
|
|
|
|
|
|
|
|
|
|||
Stock options
|
—
|
|
(1)
|
288
|
|
|
345
|
|
|||
|
|
|
|
|
|
||||||
Potentially anti-dilutive shares excluded from diluted-per-share amounts:
|
|
|
|
|
|
|
|
|
|||
Stock options
|
2,118
|
|
(1)
|
1,347
|
|
|
688
|
|
|
2015
|
||
Net sales
|
$
|
—
|
|
|
|
||
Income before income tax provision
|
$
|
2,604
|
|
Income tax provision
|
488
|
|
|
Income from discontinued operations
|
$
|
2,116
|
|
|
|
Total
|
||
Liability balance at December 31, 2014
|
|
$
|
—
|
|
Increase in liability
|
|
3,306
|
|
|
Reduction in liability (payments)
|
|
(2,462
|
)
|
|
Liability balance at December 31, 2015
|
|
$
|
844
|
|
Increase in liability
|
|
200
|
|
|
Reduction in liability (payments)
|
|
(995
|
)
|
|
Liability balance at December 31, 2016
|
|
$
|
49
|
|
Increase in liability
|
|
1,483
|
|
|
Reduction in liability (payments)
|
|
(782
|
)
|
|
Liability balance at December 31, 2017
|
|
$
|
750
|
|
As of December 31,
|
|
2017
|
|
2016
|
||||
Raw materials
|
|
$
|
9,522
|
|
|
$
|
14,995
|
|
Work in process
|
|
2,153
|
|
|
694
|
|
||
Finished goods
|
|
32,372
|
|
|
31,908
|
|
||
Total inventory
|
|
$
|
44,047
|
|
|
$
|
47,597
|
|
As of December 31,
|
|
2017
|
|
2016
|
||||
Land and improvements
|
|
$
|
841
|
|
|
$
|
1,996
|
|
Buildings and improvements
|
|
30,760
|
|
|
30,277
|
|
||
Machinery and equipment
|
|
25,160
|
|
|
23,699
|
|
||
Furniture and fixtures
|
|
20,385
|
|
|
19,962
|
|
||
Computer software and hardware
|
|
51,632
|
|
|
49,340
|
|
||
|
|
128,778
|
|
|
125,274
|
|
||
Accumulated depreciation and amortization
|
|
(59,672
|
)
|
|
(52,002
|
)
|
||
Total property, plant and equipment
|
|
$
|
69,106
|
|
|
$
|
73,272
|
|
As of December 31,
|
|
2017
|
|
2016
|
||||
Salaries and employee benefits
|
|
$
|
10,289
|
|
|
$
|
10,670
|
|
Sales, use and property tax (See Note 14)
|
|
3,367
|
|
|
2,376
|
|
||
Convention and meeting costs
|
|
4,970
|
|
|
5,129
|
|
||
Other
|
|
6,354
|
|
|
6,225
|
|
||
Total
|
|
$
|
24,980
|
|
|
$
|
24,400
|
|
As of December 31, 2016
|
|
Amortized
Cost |
|
Gross
Unrealized Gains |
|
Gross
Unrealized Losses |
|
Fair
Value |
||||||||
U.S. government securities funds
|
|
$
|
1,799
|
|
|
$
|
—
|
|
|
$
|
(23
|
)
|
|
$
|
1,776
|
|
Total short-term investment securities
|
|
$
|
1,799
|
|
|
$
|
—
|
|
|
$
|
(23
|
)
|
|
$
|
1,776
|
|
|
Foreign Currency
Translation
Adjustments
|
|
Net Unrealized
Gains (Losses) On
Available-For-Sale
Securities
|
|
Total
Accumulated Other
Comprehensive Loss
|
||||||
Balance as of January 1, 2015
|
$
|
(11,464
|
)
|
|
$
|
260
|
|
|
$
|
(11,204
|
)
|
Activity, net of tax
|
233
|
|
|
(272
|
)
|
|
(39
|
)
|
|||
Balance as of December 31, 2015
|
(11,231
|
)
|
|
(12
|
)
|
|
(11,243
|
)
|
|||
Activity, net of tax
|
(16
|
)
|
|
(1
|
)
|
|
(17
|
)
|
|||
Balance as of December 31, 2016
|
(11,247
|
)
|
|
(13
|
)
|
|
(11,260
|
)
|
|||
Activity, net of tax
|
1,113
|
|
|
15
|
|
|
1,128
|
|
|||
Balance as of December 31, 2017
|
$
|
(10,134
|
)
|
|
2
|
|
|
$
|
(10,132
|
)
|
Year Ended December 31,
|
|
2017
|
|
2016
|
|
2015
|
||||||
Domestic
|
|
$
|
(2,211
|
)
|
|
$
|
6,420
|
|
|
$
|
6,290
|
|
Foreign
|
|
5,433
|
|
|
2,846
|
|
|
6,990
|
|
|||
Total
|
|
$
|
3,222
|
|
|
$
|
9,266
|
|
|
$
|
13,280
|
|
Year Ended December 31,
|
|
2017
|
|
2016
|
|
2015
|
||||||
Current:
|
|
|
|
|
|
|
|
|
|
|||
Federal
|
|
$
|
(1,240
|
)
|
|
$
|
1,987
|
|
|
$
|
537
|
|
State
|
|
(23
|
)
|
|
498
|
|
|
73
|
|
|||
Foreign
|
|
4,168
|
|
|
5,345
|
|
|
4,503
|
|
|||
Subtotal
|
|
2,905
|
|
|
7,830
|
|
|
5,113
|
|
|||
Deferred:
|
|
|
|
|
|
|
|
|
|
|||
Federal
|
|
13,654
|
|
|
496
|
|
|
(3,624
|
)
|
|||
State
|
|
(248
|
)
|
|
(14
|
)
|
|
430
|
|
|||
Foreign
|
|
728
|
|
|
279
|
|
|
(179
|
)
|
|||
Subtotal
|
|
14,134
|
|
|
761
|
|
|
(3,373
|
)
|
|||
Total provision for income taxes
|
|
$
|
17,039
|
|
|
$
|
8,591
|
|
|
$
|
1,740
|
|
Year Ended December 31,
|
|
2017
|
|
2016
|
|
2015
|
|||
Statutory U.S. federal income tax rate
|
|
35.0
|
%
|
|
35.0
|
%
|
|
35.0
|
%
|
State income taxes, net of U.S. federal income tax benefit
|
|
(5.5
|
)
|
|
3.4
|
|
|
2.7
|
|
U.S. tax impact of foreign operations
|
|
1.0
|
|
|
(53.4
|
)
|
|
2.8
|
|
Valuation allowance change
|
|
405.3
|
|
|
77.6
|
|
|
(24.5
|
)
|
Unrecognized tax benefits
|
|
(91.1
|
)
|
|
4.7
|
|
|
11.2
|
|
Domestic manufacturing deduction
|
|
—
|
|
|
(2.8
|
)
|
|
(1.3
|
)
|
Permanent foreign items
|
|
53.7
|
|
|
26.8
|
|
|
(7.4
|
)
|
Non-income tax contingencies
|
|
—
|
|
|
—
|
|
|
(2.0
|
)
|
Remeasurement of deferred tax assets/liabilities
|
|
117.6
|
|
|
—
|
|
|
—
|
|
Elimination of provision on intercompany transactions
|
|
4.6
|
|
|
0.1
|
|
|
—
|
|
Other
|
|
8.2
|
|
|
1.3
|
|
|
(3.4
|
)
|
Effective income tax rate
|
|
528.8
|
%
|
|
92.7
|
%
|
|
13.1
|
%
|
Components of U.S. tax impact of foreign operations
|
|
2017
|
|
2016
|
|
2015
|
|||
Dividends received from foreign subsidiaries
|
|
65.7
|
%
|
|
65.9
|
%
|
|
5.4
|
%
|
Foreign tax credits
|
|
(4.1
|
)
|
|
(91.8
|
)
|
|
(1.1
|
)
|
Foreign tax rate differentials
|
|
(60.6
|
)
|
|
(27.1
|
)
|
|
(1.2
|
)
|
Unremitted earnings
|
|
—
|
|
|
0.2
|
|
|
(0.3
|
)
|
Other adjustments
|
|
—
|
|
|
(0.6
|
)
|
|
—
|
|
Total
|
|
1.0
|
%
|
|
(53.4
|
)%
|
|
2.8
|
%
|
As of December 31,
|
|
2017
|
|
2016
|
||||
Inventory
|
|
$
|
2,268
|
|
|
$
|
1,520
|
|
Accrued liabilities
|
|
2,190
|
|
|
4,178
|
|
||
Deferred compensation
|
|
481
|
|
|
498
|
|
||
Equity-based compensation
|
|
3,091
|
|
|
5,034
|
|
||
Intangibles assets
|
|
142
|
|
|
237
|
|
||
Bad debts
|
|
95
|
|
|
76
|
|
||
Net operating losses
|
|
13,755
|
|
|
7,143
|
|
||
Foreign tax and withholding credits
|
|
14,572
|
|
|
13,183
|
|
||
Non-income tax accruals
|
|
41
|
|
|
57
|
|
||
Health insurance accruals
|
|
125
|
|
|
257
|
|
||
Other deferred tax assets
|
|
1,869
|
|
|
1,735
|
|
||
Capital loss carryforward
|
|
82
|
|
|
510
|
|
||
Valuation allowance
|
|
(24,024
|
)
|
|
(11,250
|
)
|
||
Total deferred tax assets
|
|
14,687
|
|
|
23,178
|
|
||
Other deferred tax liabilities
|
|
(1,255
|
)
|
|
(1,597
|
)
|
||
Accelerated depreciation
|
|
(5,919
|
)
|
|
—
|
|
||
Total deferred tax liabilities
|
|
(7,174
|
)
|
|
(1,597
|
)
|
||
Total deferred taxes, net
|
|
$
|
7,513
|
|
|
$
|
21,581
|
|
As of December 31,
|
|
2017
|
|
2016
|
||||
Net deferred tax assets
|
|
$
|
8,283
|
|
|
$
|
21,590
|
|
Net deferred tax liabilities
|
|
(770
|
)
|
|
(9
|
)
|
||
Total deferred taxes, net
|
|
$
|
7,513
|
|
|
$
|
21,581
|
|
Year Ended December 31,
|
|
2017
|
|
2016
|
|
2015
|
||||||
Unrecognized tax benefits, opening balance
|
|
$
|
4,908
|
|
|
$
|
5,825
|
|
|
$
|
4,950
|
|
Settlement of liability reclassified as income tax payable
|
|
—
|
|
|
—
|
|
|
(104
|
)
|
|||
Payments on liability
|
|
—
|
|
|
—
|
|
|
—
|
|
|||
Tax positions taken in a prior period
|
|
|
|
|
|
|
|
|
|
|||
Gross increases
|
|
—
|
|
|
—
|
|
|
—
|
|
|||
Gross decreases
|
|
(705
|
)
|
|
—
|
|
|
(47
|
)
|
|||
Tax positions taken in the current period
|
|
|
|
|
|
|
|
|
|
|||
Gross increases
|
|
716
|
|
|
1,182
|
|
|
1,252
|
|
|||
Gross decreases
|
|
—
|
|
|
—
|
|
|
—
|
|
|||
Lapse of applicable statute of limitations
|
|
(1,970
|
)
|
|
(2,121
|
)
|
|
(69
|
)
|
|||
Currency translation adjustments
|
|
7
|
|
|
22
|
|
|
(157
|
)
|
|||
Unrecognized tax benefits, ending balance
|
|
$
|
2,956
|
|
|
$
|
4,908
|
|
|
$
|
5,825
|
|
|
Number of
Shares
|
|
Weighted Average Exercise
Price Per Share
|
|||
Options outstanding at January 1, 2015
|
2,037
|
|
|
$
|
11.69
|
|
Granted
|
335
|
|
|
14.04
|
|
|
Forfeited or canceled
|
(284
|
)
|
|
14.07
|
|
|
Exercised
|
(405
|
)
|
|
9.78
|
|
|
Options outstanding at December 31, 2015
|
1,683
|
|
|
12.21
|
|
|
Granted
|
—
|
|
|
—
|
|
|
Forfeited or canceled
|
(124
|
)
|
|
11.95
|
|
|
Exercised
|
(35
|
)
|
|
4.74
|
|
|
Options outstanding at December 31, 2016
|
1,524
|
|
|
12.41
|
|
|
Granted
|
25
|
|
|
13.50
|
|
|
Forfeited or canceled
|
(142
|
)
|
|
14.69
|
|
|
Exercised
|
(17
|
)
|
|
12.06
|
|
|
Options outstanding at December 31, 2017
|
1,390
|
|
|
$
|
12.20
|
|
|
2017
|
|
2016
|
|
2015
|
||||||
Weighted average grant date fair value of grants
|
$
|
4.94
|
|
|
$
|
—
|
|
|
$
|
4.79
|
|
Expected life (in years)
|
5.0
|
|
|
—
|
|
|
5.0 to 6.0
|
|
|||
Risk-free interest rate
|
1.8
|
|
|
—
|
|
|
1.5 to 1.8
|
|
|||
Expected volatility
|
39.8
|
|
|
—
|
|
|
42.6 to 52.3
|
|
|||
Dividend yield
|
—
|
|
|
—
|
|
|
2.8 to 3.6
|
|
|
|
Options Outstanding
|
|
Options Exercisable
|
||||||||||||||
Range of Option
Prices Per Share
|
|
Options
Outstanding
|
|
Weighted-Avg.
Remaining
Contractual Life
|
|
Weighted-Avg.
Exercise Price
Per Share
|
|
Options
Exercisable
|
|
Weighted-Avg.
Remaining
Contractual Life
|
|
Weighted-Avg.
Exercise Price
Per Share
|
||||||
$2.35 to $9.99
|
|
152
|
|
|
2.3
|
|
$
|
5.38
|
|
|
152
|
|
|
2.3
|
|
$
|
5.38
|
|
$10.00 to $13.99
|
|
938
|
|
|
4.9
|
|
12.42
|
|
|
903
|
|
|
4.9
|
|
12.36
|
|
||
$14.00 to $17.70
|
|
300
|
|
|
6.7
|
|
14.98
|
|
|
238
|
|
|
6.6
|
|
15.17
|
|
||
|
|
1,390
|
|
|
|
|
|
|
|
1,293
|
|
|
|
|
|
|
|
Number of
Shares
|
|
Weighted Average
Grant Date
Fair Value
|
|||
Units outstanding at January 1, 2015
|
180
|
|
|
$
|
15.09
|
|
Granted
|
679
|
|
|
12.61
|
|
|
Issued
|
(30
|
)
|
|
13.63
|
|
|
Forfeited
|
(85
|
)
|
|
12.84
|
|
|
Units outstanding at December 31, 2015
|
744
|
|
|
12.48
|
|
|
Granted
|
281
|
|
|
9.49
|
|
|
Issued
|
(154
|
)
|
|
13.05
|
|
|
Forfeited
|
(33
|
)
|
|
12.20
|
|
|
Units outstanding at December 31, 2016
|
838
|
|
|
11.39
|
|
|
Granted
|
274
|
|
|
12.62
|
|
|
Issued
|
(187
|
)
|
|
12.23
|
|
|
Forfeited
|
(197
|
)
|
|
12.07
|
|
|
Units outstanding at December 31, 2017
|
728
|
|
|
11.56
|
|
Year Ending December 31,
|
|
||
2018
|
$
|
5,918
|
|
2019
|
3,210
|
|
|
2020
|
2,604
|
|
|
2021
|
2,139
|
|
|
2022
|
2,042
|
|
|
Thereafter
|
12,148
|
|
|
Total
|
$
|
28,061
|
|
Year Ended December 31,
|
|
2017
|
|
2016
|
|
2015
|
||||||
Net sales:
|
|
|
|
|
|
|
|
|
|
|||
NSP Americas
|
|
$
|
166,017
|
|
|
$
|
175,922
|
|
|
$
|
179,151
|
|
NSP Russia, Central and Eastern Europe
|
|
32,190
|
|
|
29,998
|
|
|
31,469
|
|
|||
Synergy WorldWide
|
|
123,833
|
|
|
124,793
|
|
|
114,081
|
|
|||
NSP China
|
|
19,989
|
|
|
10,446
|
|
|
4
|
|
|||
Total net sales
|
|
342,029
|
|
|
341,159
|
|
|
324,705
|
|
|||
Contribution margin (1):
|
|
|
|
|
|
|
|
|
|
|||
NSP Americas
|
|
69,408
|
|
|
75,005
|
|
|
74,953
|
|
|||
NSP Russia, Central and Eastern Europe
|
|
10,930
|
|
|
10,525
|
|
|
11,340
|
|
|||
Synergy WorldWide
|
|
35,377
|
|
|
38,034
|
|
|
35,277
|
|
|||
NSP China
|
|
15,307
|
|
|
6,748
|
|
|
4
|
|
|||
Total contribution margin
|
|
131,022
|
|
|
130,312
|
|
|
121,574
|
|
|||
|
|
|
|
|
|
|
||||||
Selling, general and administrative (2)
|
|
129,635
|
|
|
120,273
|
|
|
107,702
|
|
|||
Operating income
|
|
1,387
|
|
|
10,039
|
|
|
13,872
|
|
|||
|
|
|
|
|
|
|
||||||
Other income (loss), net
|
|
1,835
|
|
|
(773
|
)
|
|
(592
|
)
|
|||
Income from continuing operations before provision for income taxes
|
|
$
|
3,222
|
|
|
$
|
9,266
|
|
|
$
|
13,280
|
|
Year Ended December 31,
|
|
2017
|
|
2016
|
|
2015
|
||||||
Capital expenditures:
|
|
|
|
|
|
|
|
|
|
|||
NSP Americas
|
|
$
|
3,965
|
|
|
$
|
8,999
|
|
|
$
|
21,437
|
|
NSP Russia, Central and Eastern Europe
|
|
55
|
|
|
131
|
|
|
—
|
|
|||
Synergy WorldWide
|
|
763
|
|
|
564
|
|
|
302
|
|
|||
NSP China
|
|
603
|
|
|
430
|
|
|
487
|
|
|||
Total capital expenditures
|
|
$
|
5,386
|
|
|
$
|
10,124
|
|
|
$
|
22,226
|
|
|
|
|
|
|
|
|
||||||
Depreciation and amortization:
|
|
|
|
|
|
|
|
|
|
|||
NSP Americas
|
|
$
|
7,884
|
|
|
$
|
3,997
|
|
|
$
|
3,603
|
|
NSP Russia, Central and Eastern Europe
|
|
60
|
|
|
42
|
|
|
26
|
|
|||
Synergy WorldWide
|
|
621
|
|
|
713
|
|
|
885
|
|
|||
NSP China
|
|
69
|
|
|
56
|
|
|
11
|
|
|||
Total depreciation and amortization
|
|
$
|
8,634
|
|
|
$
|
4,808
|
|
|
$
|
4,525
|
|
As of December 31,
|
|
2017
|
|
2016
|
||||
Assets:
|
|
|
|
|
|
|
||
NSP Americas
|
|
$
|
127,246
|
|
|
$
|
146,761
|
|
NSP Russia, Central and Eastern Europe
|
|
6,664
|
|
|
6,106
|
|
||
Synergy WorldWide
|
|
44,047
|
|
|
39,083
|
|
||
NSP China
|
|
17,238
|
|
|
13,620
|
|
||
Total assets
|
|
$
|
195,195
|
|
|
$
|
205,570
|
|
Year Ended December 31,
|
|
2017
|
|
2016
|
|
2015
|
||||||
Net sales:
|
|
|
|
|
|
|
|
|
|
|||
United States
|
|
$
|
140,860
|
|
|
$
|
148,060
|
|
|
$
|
147,553
|
|
South Korea
|
|
52,020
|
|
|
57,637
|
|
|
48,476
|
|
|||
Other
|
|
149,149
|
|
|
135,462
|
|
|
128,676
|
|
|||
Total net sales
|
|
$
|
342,029
|
|
|
$
|
341,159
|
|
|
$
|
324,705
|
|
Year Ended December 31,
|
|
2017
|
|
2016
|
|
2015
|
||||||
NSP Americas:
|
|
|
|
|
|
|
|
|
|
|||
General health
|
|
$
|
74,492
|
|
|
$
|
78,187
|
|
|
$
|
80,315
|
|
Immunity
|
|
20,451
|
|
|
19,185
|
|
|
22,042
|
|
|||
Cardiovascular
|
|
11,454
|
|
|
12,677
|
|
|
12,331
|
|
|||
Digestive
|
|
45,231
|
|
|
47,659
|
|
|
49,239
|
|
|||
Personal care
|
|
7,260
|
|
|
7,537
|
|
|
3,575
|
|
|||
Weight management
|
|
7,129
|
|
|
10,677
|
|
|
11,649
|
|
|||
|
|
166,017
|
|
|
175,922
|
|
|
179,151
|
|
|||
NSP Russia, Central and Eastern Europe:
|
|
|
|
|
|
|
|
|
|
|||
General health
|
|
$
|
14,813
|
|
|
$
|
12,907
|
|
|
$
|
13,332
|
|
Immunity
|
|
3,530
|
|
|
3,349
|
|
|
3,853
|
|
|||
Cardiovascular
|
|
2,166
|
|
|
2,212
|
|
|
2,006
|
|
|||
Digestive
|
|
8,261
|
|
|
8,009
|
|
|
8,178
|
|
|||
Personal care
|
|
2,330
|
|
|
2,370
|
|
|
2,809
|
|
|||
Weight management
|
|
1,090
|
|
|
1,151
|
|
|
1,291
|
|
|||
|
|
32,190
|
|
|
29,998
|
|
|
31,469
|
|
|||
Synergy WorldWide:
|
|
|
|
|
|
|
|
|
|
|||
General health
|
|
$
|
31,973
|
|
|
$
|
35,283
|
|
|
$
|
43,829
|
|
Immunity
|
|
508
|
|
|
620
|
|
|
752
|
|
|||
Cardiovascular
|
|
50,702
|
|
|
51,684
|
|
|
34,191
|
|
|||
Digestive
|
|
16,121
|
|
|
12,536
|
|
|
17,746
|
|
|||
Personal care
|
|
8,532
|
|
|
8,981
|
|
|
5,697
|
|
|||
Weight management
|
|
15,997
|
|
|
15,689
|
|
|
11,866
|
|
|||
|
|
123,833
|
|
|
124,793
|
|
|
114,081
|
|
|||
NSP China:
|
|
|
|
|
|
|
|
|
|
|||
General health
|
|
$
|
3,738
|
|
|
$
|
1,551
|
|
|
$
|
4
|
|
Immunity
|
|
468
|
|
|
370
|
|
|
—
|
|
|||
Cardiovascular
|
|
3,886
|
|
|
2,617
|
|
|
—
|
|
|||
Digestive
|
|
8,361
|
|
|
4,323
|
|
|
—
|
|
|||
Personal care
|
|
350
|
|
|
629
|
|
|
—
|
|
|||
Weight management
|
|
3,186
|
|
|
956
|
|
|
—
|
|
|||
|
|
19,989
|
|
|
10,446
|
|
|
4
|
|
|||
Total net sales
|
|
$
|
342,029
|
|
|
$
|
341,159
|
|
|
$
|
324,705
|
|
As of December 31
|
|
2017
|
|
2016
|
||||
Property, plant and equipment
|
|
|
|
|
|
|
||
United States
|
|
$
|
65,928
|
|
|
$
|
70,770
|
|
Other
|
|
3,178
|
|
|
2,502
|
|
||
Total property, plant and equipment
|
|
$
|
69,106
|
|
|
$
|
73,272
|
|
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
|
||||||||
|
Quoted Prices
in Active
Markets for
Identical Assets
|
|
Significant
Other
Observable
Inputs
|
|
Significant
Unobservable
Inputs
|
|
Total
|
||||||||
Investment securities - trading
|
$
|
1,980
|
|
|
—
|
|
|
—
|
|
|
$
|
1,980
|
|
||
Total assets measured at fair value on a recurring basis
|
$
|
1,980
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
1,980
|
|
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
|
||||||||
|
Quoted Prices
in Active
Markets for
Identical Assets
|
|
Significant
Other
Observable
Inputs
|
|
Significant
Unobservable
Inputs
|
|
Total
|
||||||||
Investments available-for-sale
|
|
|
|
|
|
|
|
|
|
|
|
||||
U.S. government security funds
|
$
|
1,776
|
|
|
—
|
|
|
—
|
|
|
$
|
1,776
|
|
||
Investment securities - trading
|
1,391
|
|
|
—
|
|
|
—
|
|
|
1,391
|
|
||||
Total assets measured at fair value on a recurring basis
|
$
|
3,167
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
3,167
|
|
|
For the Quarter Ended
|
||||||||||||||
|
March 31,
2017 |
|
June 30,
2017 |
|
September 30,
2017 |
|
December 31,
2017 |
||||||||
Net sales
|
$
|
83,098
|
|
|
$
|
81,344
|
|
|
$
|
89,301
|
|
|
$
|
88,286
|
|
Cost of sales
|
(21,728
|
)
|
|
(21,197
|
)
|
|
(23,505
|
)
|
|
(24,607
|
)
|
||||
Gross profit
|
61,370
|
|
|
60,147
|
|
|
65,796
|
|
|
63,679
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Volume incentives
|
28,983
|
|
|
28,288
|
|
|
30,716
|
|
|
31,983
|
|
||||
Selling, general and administrative
|
30,336
|
|
|
31,836
|
|
|
32,926
|
|
|
34,537
|
|
||||
Operating income (loss)
|
2,051
|
|
|
23
|
|
|
2,154
|
|
|
(2,841
|
)
|
||||
Other income (expense)
|
1,275
|
|
|
441
|
|
|
193
|
|
|
(74
|
)
|
||||
Income (loss) before income taxes
|
3,326
|
|
|
464
|
|
|
2,347
|
|
|
(2,915
|
)
|
||||
Provision (benefit) for income taxes
|
1,463
|
|
|
884
|
|
|
(1
|
)
|
|
14,693
|
|
||||
Net income (loss)
|
1,863
|
|
|
(420
|
)
|
|
2,348
|
|
|
(17,608
|
)
|
||||
Net loss attributable to noncontrolling interests
|
(297
|
)
|
|
(233
|
)
|
|
(95
|
)
|
|
(250
|
)
|
||||
Net income (loss) attributable to common shareholders
|
$
|
2,160
|
|
|
$
|
(187
|
)
|
|
$
|
2,443
|
|
|
$
|
(17,358
|
)
|
|
|
|
|
|
|
|
|
||||||||
Basic and diluted net income (loss) per common share:
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Basic earnings (loss) per share attributable to common shareholders:
|
$
|
0.11
|
|
|
$
|
(0.01
|
)
|
|
$
|
0.13
|
|
|
$
|
(0.92
|
)
|
|
|
|
|
|
|
|
|
||||||||
Diluted earnings (loss) per share attributable to common shareholders:
|
$
|
0.11
|
|
|
$
|
(0.01
|
)
|
|
$
|
0.13
|
|
|
$
|
(0.92
|
)
|
|
|
|
|
|
|
|
|
||||||||
Dividends declared per common share
|
$
|
0.10
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
For the Quarter Ended
|
||||||||||||||
|
March 31,
2016 |
|
June 30,
2016 |
|
September 30,
2016 |
|
December 31,
2016 |
||||||||
Net sales
|
$
|
82,402
|
|
|
$
|
89,366
|
|
|
$
|
85,441
|
|
|
$
|
83,950
|
|
Cost of sales
|
(22,020
|
)
|
|
(23,078
|
)
|
|
(21,512
|
)
|
|
(24,327
|
)
|
||||
Gross profit
|
60,382
|
|
|
66,288
|
|
|
63,929
|
|
|
59,623
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Volume incentives
|
29,877
|
|
|
30,791
|
|
|
29,684
|
|
|
29,558
|
|
||||
Selling, general and administrative
|
28,385
|
|
|
31,249
|
|
|
29,187
|
|
|
31,452
|
|
||||
Operating income (loss)
|
2,120
|
|
|
4,248
|
|
|
5,058
|
|
|
(1,387
|
)
|
||||
Other income (expense), net
|
1,559
|
|
|
(622
|
)
|
|
20
|
|
|
(1,730
|
)
|
||||
Income (loss) before income taxes
|
3,679
|
|
|
3,626
|
|
|
5,078
|
|
|
(3,117
|
)
|
||||
Provision for income taxes
|
1,890
|
|
|
1,260
|
|
|
1,136
|
|
|
4,305
|
|
||||
Net income (loss)
|
1,789
|
|
|
2,366
|
|
|
3,942
|
|
|
(7,422
|
)
|
||||
Net loss attributable to noncontrolling interests
|
(280
|
)
|
|
(202
|
)
|
|
(213
|
)
|
|
(769
|
)
|
||||
Net income (loss) attributable to common shareholders
|
$
|
2,069
|
|
|
$
|
2,568
|
|
|
$
|
4,155
|
|
|
$
|
(6,653
|
)
|
|
|
|
|
|
|
|
|
||||||||
Basic and diluted net income (loss) per common share:
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Basic earnings (loss) per share attributable to common shareholders:
|
$
|
0.11
|
|
|
$
|
0.14
|
|
|
$
|
0.22
|
|
|
$
|
(0.35
|
)
|
|
|
|
|
|
|
|
|
||||||||
Diluted earnings (loss) per share attributable to common shareholders:
|
$
|
0.11
|
|
|
$
|
0.14
|
|
|
$
|
0.22
|
|
|
$
|
(0.35
|
)
|
|
|
|
|
|
|
|
|
||||||||
Dividends declared per common share
|
$
|
0.10
|
|
|
$
|
0.10
|
|
|
$
|
0.10
|
|
|
$
|
0.10
|
|
/s/ Deloitte & Touche LLP
|
|
|
|
Salt Lake City, Utah
|
|
March 16, 2018
|
|
(a)(1)
|
List of Financial Statements
|
|
|
|
The following are filed as part of this report:
|
|
|
|
Report of Independent Registered Public Accounting Firm
|
|
|
|
Consolidated balance sheets as of December 31, 2017 and 2016
|
|
|
|
Consolidated statements of operations for the years ended December 31, 2017, 2016, and 2015
|
|
|
|
Consolidated statements of comprehensive income (loss) for the years ended December 31, 2017, 2016, and 2015
|
|
|
|
Consolidated statements of changes in shareholders’ equity for the years ended December 31, 2017, 2016, and 2015
|
|
|
|
Consolidated statements of cash flows for the years ended December 31, 2017, 2016, and 2015
|
|
|
|
Notes to consolidated financial statements
|
|
|
(a)(2)
|
List of Financial Statement Schedules
|
|
|
|
Schedule II - Valuation and Qualifying Accounts.
|
|
|
|
Financial statement schedules other than the one listed are omitted for the reason that they are not required or are not applicable, or the required information is shown in the financial statements or notes thereto, or contained elsewhere in this report.
|
|
|
(a)(3)
|
List of Exhibits
|
|
|
|
Exhibit Index as seen below
|
Date:
|
March 16, 2018
|
By:
|
/s/ Gregory L. Probert
|
|
|
|
Gregory L. Probert,
|
|
|
|
Chief Executive Officer and Chairman of the Board
|
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
/s/ Gregory L. Probert
|
|
Chief Executive Officer and Chairman of the Board
|
|
March 16, 2018
|
Gregory L. Probert
|
|
(Principal Executive Officer)
|
|
|
|
|
|
|
|
/s/ Kristine F. Hughes
|
|
Vice Chair of the Board
|
|
March 16, 2018
|
Kristine F. Hughes
|
|
|
|
|
|
|
|
|
|
/s/ Joseph W. Baty
|
|
Executive Vice President,
|
|
March 16, 2018
|
Joseph W. Baty
|
|
Chief Financial Officer and Treasurer (Principal Financial and Accounting Officer)
|
|
|
|
|
|
|
|
/s/ Albert R. Dowden
|
|
Director
|
|
March 16, 2018
|
Albert R. Dowden
|
|
|
|
|
|
|
|
|
|
/s/ Jia Hongfei
|
|
Director
|
|
March 16, 2018
|
Jia Hongfei
|
|
|
|
|
|
|
|
|
|
/s/ Robert B. Mercer
|
|
Director
|
|
March 16, 2018
|
Robert B. Mercer
|
|
|
|
|
|
|
|
|
|
/s/ J. Christopher Teets
|
|
Director
|
|
March 16, 2018
|
J. Christopher Teets
|
|
|
|
|
|
|
|
|
|
/s/ Mary Beth Springer
|
|
Director
|
|
March 16, 2018
|
Mary Beth Springer
|
|
|
|
|
|
|
|
|
|
/s/ Rebecca Lee Steinfort
|
|
Director
|
|
March 16, 2018
|
Rebecca Lee Steinfort
|
|
|
|
|
|
|
|
|
|
/s/ Robert D. Straus
|
|
Director
|
|
March 16, 2018
|
Robert D. Straus
|
|
|
|
|
|
|
|
|
|
/s/ Jeffrey D. Watkins
|
|
Director
|
|
March 16, 2018
|
Jeffrey D. Watkins
|
|
|
|
|
Description
|
|
Balance at
Beginning
of Year
|
|
Provisions
|
|
Amounts
Written Off
|
|
Amounts
Recovered
|
|
Effect of
Currency
Translation
|
|
Balance at
End of Year
|
||||||||||||
Year Ended December 31, 2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Allowance for doubtful accounts receivable
|
|
$
|
205
|
|
|
$
|
556
|
|
|
$
|
(366
|
)
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
395
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Allowance for sales returns
|
|
156
|
|
|
1,746
|
|
|
(1,644
|
)
|
|
—
|
|
|
12
|
|
|
270
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Tax valuation allowance
|
|
11,250
|
|
|
13,786
|
|
|
—
|
|
|
(865
|
)
|
|
(147
|
)
|
|
24,024
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Year Ended December 31, 2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Allowance for doubtful accounts receivable
|
|
$
|
190
|
|
|
$
|
305
|
|
|
$
|
(290
|
)
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
205
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Allowance for sales returns
|
|
94
|
|
|
1,435
|
|
|
(1,368
|
)
|
|
—
|
|
|
(5
|
)
|
|
156
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Tax valuation allowance
|
|
6,565
|
|
|
5,638
|
|
|
(493
|
)
|
|
—
|
|
|
(460
|
)
|
|
11,250
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Year Ended December 31, 2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Allowance for doubtful accounts receivable
|
|
$
|
849
|
|
|
$
|
83
|
|
|
$
|
(714
|
)
|
|
$
|
—
|
|
|
$
|
(28
|
)
|
|
$
|
190
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Allowance for sales returns
|
|
129
|
|
|
1,126
|
|
|
(1,155
|
)
|
|
—
|
|
|
(6
|
)
|
|
94
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Tax valuation allowance
|
|
13,169
|
|
|
(6,088
|
)
|
|
—
|
|
|
—
|
|
|
(516
|
)
|
|
6,565
|
|
Item No.
|
|
Exhibit
|
3.1(1)
|
|
|
3.2(1)
|
|
|
10.1(2)*
|
|
|
10.2(3)*
|
|
|
10.3(4)
|
|
|
10.4(4)*
|
|
|
10.5(5)*
|
|
|
10.6(6)*
|
|
|
10.7(7)
|
|
|
10.8(7)*
|
|
|
10.9(8)*
|
|
|
10.10(8)*
|
|
|
10.11(2)*
|
|
|
10.12(2)*
|
|
|
10.13(9)*
|
|
|
10.14(1)
|
|
|
21(1)
|
|
|
23.1(1)
|
|
|
31.1(1)
|
|
|
31.2(1)
|
|
|
32.1(1)
|
|
|
32.2(1)
|
|
|
101.INS
|
|
XBRL Instance Document
|
101.SCH
|
|
XBRL Taxonomy Extension Schema Document
|
101.CAL
|
|
XBRL Taxonomy Extension Calculation Linkbase Document
|
101.LAB
|
|
XBRL Taxonomy Extension Label Linkbase Document
|
101.PRE
|
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
101.DEF
|
|
XBRL Taxonomy Extension Definition Linkbase Document
|
(1)
|
|
Filed herewith.
|
(2)
|
|
Previously filed with the SEC on March 13, 2015, as an exhibit to the Annual Report on Form 10-K and is incorporated herein by reference.
|
(3)
|
|
Previously filed with the SEC on March 14, 2016, as an exhibit to the Annual Report on Form 10-K and is incorporated herein by reference.
|
(4)
|
|
Previously filed with the SEC on October 19, 2009 as Appendix C, an exhibit to the Registrant’s Proxy Statement and is incorporated herein by reference.
|
(5)
|
|
Filed with the SEC on February 19, 2015, as an exhibit to the Current Report on Form 8-K and is incorporated herein by reference.
|
(6)
|
|
Filed with the SEC on June 22, 2011, as an exhibit to the Current Report on Form 8-K and is incorporated herein by reference.
|
(7)
|
|
Filed with the SEC on January 15, 2015, as an exhibit to the Current Report on Form 8-K and is incorporated herein by reference.
|
(8)
|
|
Filed with the SEC on March 17, 2014, as an exhibit to the Annual Report on Form 10-K and is incorporated herein by reference.
|
(9)
|
|
Filed with the SEC on November 3, 2016, as an exhibit to the Current Report on Form 8-K and is incorporated herein by reference.
|
*
|
|
Management contract or compensatory plan.
|
1.
|
The name of the Corporation is Nature’s Sunshine Products, Inc.
|
2.
|
The text of the amendments (collectively, the “
Amendments
”) to the Amended and Restated Articles of Incorporation of the Corporation are set forth below.
|
3.
|
The Amendments were adopted by the Corporation’s shareholders at an annual meeting of shareholders held on May 8, 2013 (the “
Shareholders’ Meeting
”), in accordance with the requirements of the Utah Act.
|
4.
|
The Corporation has 15,853,760 shares of Common Stock outstanding and eligible to vote on the Amendments. The number of Common Stock votes indisputably represented at the Shareholders’ Meeting was 13,803,430. At the Shareholders’ Meeting, votes represented by the Common Stock were cast in favor of the Amendments as set forth below. The number of votes cast in favor of the Amendments was sufficient for approval of the Amendments.(1)
|
|
|
(1) In accordance with Article IX of the prior Amended and Restated Articles of Incorporation, the approval of these amendments required the vote of at least 75% of the shares outstanding and entitled to vote on the amendments.
|
|
|
Voting
|
|
||||
Amendment
|
|
For
|
|
Against
|
|
Abstain
|
|
Amendments to Articles of Incorporation to phase out the classified Board of Directors.
|
|
12,303,103
|
|
27,966
|
|
11,893
|
|
|
|
For
|
|
Against
|
|
Abstain
|
|
Amendments to Articles of Incorporation to eliminate the supermajority voting requirement with respect to the removal of directors.
|
|
12,308,080
|
|
26,191
|
|
8,690
|
|
|
|
For
|
|
Against
|
|
Abstain
|
|
Amendments to Articles of Incorporation to eliminate the supermajority voting requirement with respect to amendments to Article VI of the prior articles.
|
|
12,303,808
|
|
30,261
|
|
8,893
|
|
|
NATURE’S SUNSHINE, INC.
|
|
|
|
|
|
By:
|
/s/ Jamon A. Jarvis
|
|
Name:
|
Jamon A. Jarvis
|
|
Its:
|
General Counsel, Chief Compliance Officer & Secretary
|
|
|
Voting
|
||||
Amendment
|
|
For
|
|
Against
|
|
Abstain
|
Amendments to Articles of Incorporation to modify or remove certain provisions and to make other technical changes.
|
|
12,908,912
|
|
28,140
|
|
6,357
|
|
|
|
|
|
|
|
|
|
For
|
|
Against
|
|
Abstain
|
|
|
12,915,501
|
|
18,870
|
|
9,037
|
|
|
|
|
|
|
|
|
|
For
|
|
Against
|
|
Abstain
|
Amendments to Articles of Incorporation to authorize the Board of Directors to adopt, amend, alter and repeal the Bylaws.
|
|
12,608,955
|
|
328,085
|
|
6,367
|
|
|
|
|
|
|
|
|
|
For
|
|
Against
|
|
Abstain
|
Amendment to Articles of Incorporation to modify certain provisions relating to the terms of directors.
|
|
12,889,954
|
|
47,344
|
|
6,109
|
|
|
|
|
|
|
|
|
|
For
|
|
Against
|
|
Abstain
|
Amendments to Articles of Incorporation to eliminate personal liability, to the extent permitted by law, of the Company’s directors and officers and provide indemnification of its directors, officers, employees, fiduciaries and agents.
|
|
12,883,703
|
|
56,246
|
|
3,458
|
|
|
|
|
|
|
|
|
|
For
|
|
Against
|
|
Abstain
|
Amendment to Articles of Incorporation to increase authorized shares of common stock from 20,000,000 to 50,000,000 and to clarify certain rights and preferences of common stock.
|
|
12,578,252
|
|
359,096
|
|
6,059
|
|
|
|
|
|
|
|
|
|
For
|
|
Against
|
|
Abstain
|
Amendments to Articles of Incorporation to create a new class of stock designated as preferred stock and to authorize the issuance of up to 10,000,000 shares of preferred stock.
|
|
12,502,357
|
|
434,033
|
|
7,017
|
|
|
|
|
|
|
|
|
|
For
|
|
Against
|
|
Abstain
|
Amendment to Articles of Incorporation to require a showing of cause for shareholders to remove directors.
|
|
12,566,256
|
|
372,952
|
|
4,200
|
|
|
|
|
|
|
|
|
|
For
|
|
Against
|
|
Abstain
|
Amendment to Articles of Incorporation to require shareholders to act by shareholder meeting and not by written consent.
|
|
12,579,866
|
|
354,378
|
|
9,164
|
|
|
|
|
|
|
|
|
|
For
|
|
Against
|
|
Abstain
|
Amendment to Articles of Incorporation to enhance shareholder voting requirements to adopt, amend or repeal bylaws.
|
|
12,584,231
|
|
352,584
|
|
6,592
|
|
|
|
|
|
|
|
|
|
For
|
|
Against
|
|
Abstain
|
Amendments to Articles of Incorporation to authorize the Board of Directors to fix the number of directors and to fill vacancies on the Board.
|
|
12,580,776
|
|
357,813
|
|
4,820
|
|
|
|
|
|
|
|
|
|
For
|
|
Against
|
|
Abstain
|
Amendment to Articles of Incorporation and the Bylaws to enhance shareholder voting requirements to alter, amend or repeal certain provisions of the Articles of Incorporation and the Bylaws.
|
|
12,577,179
|
|
359,984
|
|
6,245
|
AMENDED AND RESTATED BYLAWS
OF
NATURE’S SUNSHINE PRODUCTS, INC.
___________________
March 9, 2018
___________________
|
(a)
|
The name of the corporation and that it is organized under the laws of the State of Utah.
|
(b)
|
The name of the person to whom the certificate is issued.
|
(c)
|
The number and class of shares, and the designation of the series, if any, which such certificate represents.
|
1.
|
Employment.
|
1.
|
Positions and Duties
. Executivee will serve as
President - International
of the Company, reporting directly to the Chief Executive Officer ("CEO") of the Company. In addition, without additional compensation, if requested by the Company, Executive will serve in other officer positions of the Company and its subsidiaries. Executive shall devote his best efforts and substantially all of his business time and services to the Company to perform such duties as may be customarily incident to such position of an enterprise of the size and nature of the Company and as may reasonably be assigned from time to time by the CEO of the Company. or the Company, as the case may be. Executive will render his services hereunder to the Company, shall use his best efforts, judgment and energy in the performance of the duties assigned to him, and shall abide by the Company's Code of Conduct and any. other applicable Company policies, and shall comply with any and all applicable laws, including but not limited to insider trading/reporting requirements and the policies and procedures as may be set forth in the employee handbook, manuals and other materials provided by the Company.
|
2.
|
Place of Performance
. Executive shall perform his services hereunder at the Company's executive offices in Provo, Utah;
provided, however
, that Executive will be required to travel from time to time as reasonably required for business purposes.
|
2.
|
Compensation and Benefits.
|
1.
|
Base Salary
. Executive shall receive an annual salary of
$160,360.00
paid in accordance with the Company's payroll practices, as in effect from time to time. Base salary shall be subject to review on at least an annual basis by the CEO. Executive understands that no further compensation will be given for his/her name being used as an officer or shareholder on any corporation, subsidiary or branch.
|
2.
|
Discretionary Bonus.
Executive shall also be eligible to participate in the executive bonus program or any successor program (the "EBP"). Payment of any bonus under the EBP is in NSP’s sole discretion and such payments will be made in accordance with section 409A.
|
3.
|
Employee Benefits
. Executive will be eligible to participate in retirement/savings, health insurance, term lifè insurance, long term disability insurance and other employee benefit plans, policies or arrangements maintained by the Company for its employees generally and, at the discretion of the Board, in incentive plans, stock option plans and change in control severance plans maintained by the Company for its executives. if any, subject to the terms and conditions of such plans, policies or arrangements. including but not limited to those benefits outlined in the Employee Handbook.
|
4.
|
Stock Options
. The Company may from time to time grant to Executive options (the "Options") to purchase shares of NSP common stock pursuant to the price, terms and conditions set forth in the then applicable Stock Option Plan, as amended from time to time, or as otherwise set forth in a Stock Option Agreement.
|
3.
|
Indemnification; D&O Insurance.
|
4.
|
Expenses. In accordance with the Company's normal policies for expense reimbursement, the Company shall reimburse Executive for all reasonable travel, entertainment and other expenses incurred or paid by Executive in connection with, or related to, the performance of Executive's duties, responsibilities or services under this Agreement, upon presentation of documentation, including expense statements, vouchers and/or such other supporting information as the Company may request.
|
5.
|
Termination. Upon cessation of his employment with the Company, Executive will be entitled only to such compensation and benefits as described in this Section 5.
|
1.
|
Termination without Cause
. If Executive's employment by the Company is terminated by the Company without Cause (as defined below), Executive will be entitled to:
|
1.
|
payment of all accrued and unpaid base salary through the date of such termination;
|
2.
|
monthly severance payments equal to one-twelfth of Executive's base salary as of the date of such termination for a period equal to twelve (12) months (the "Severance Period").
|
3.
|
payment of the cost for continuation of Executive's health insurance coverage under COBRA (and for his or her family members if Executive provided for their coverage during his or her employment) during the Severance Period and in accord with the NSP plan applicable to NSP employees currently in effect.
|
2.
|
Release
. Notwithstanding any provision of this Agreement, the payments and benefits described above are conditioned on Executive's execution and delivery to the Company of a release substantially identical to that attached hereto as Exhibit A in a manner consistent with the requirements of the Older Workers Benefit Protection Act, if applicable, and any applicable state law (the "Release"). The severance benefits described in Section 5.1.2 will be paid after the Release becomes irrevocable.
|
3.
|
Termination for Cause
. If Executive's employment with the Company is terminated by the Company for Cause then the Company's obligation to Executive will be limited solely to the payment of accrued and unpaid base salary through the date of such termination. To terminate Executive's employment for Cause, the CEO, in consultation with the Board of Directors, must determine in good faith that Cause has occurred.
|
1.
|
"Cause" means:
|
a)
|
continuing performance by Executive deemed unsatisfactory to NSP acting reasonably and in good faith or conduct by Executive deemed unacceptable by NSP acting reasonably and in good faith;
|
b)
|
conviction of, or the entry of a plea of guilty or no contest to, a felony or any crime that may materially adversely affect the business, standing or reputation of the Company;
|
c)
|
dishonesty, fraud, embezzlement or other misappropriation of funds;
|
d)
|
material breach of this Agreement:
|
e)
|
willful refusal to perform the lawful and reasonable directives of the CEO or the Board.
|
4.
|
Resignation by Executive.
Executive may resign his/her employment by giving the Company four weeks' notice of said resignation; NSP may elect to pay Employee's base salary in lieu of notice. If Executive resigns, then the Company's obligation to Executive will be limited solely to the payment of accrued and unpaid base salary through the date of such termination.
|
5.
|
Termination upon Death or Incapacity of Executive
. Executive's employment with the Company shall terminate upon the death or incapacity of Executive. In the event of termination of Executive's employment by reason of Executive's death or incapacity, the provisions governing termination without cause, above, shall apply. "Incapacity" shall mean that Executive is, for a period of 90 days or more, unable to perform Executive's duties effectively, for reasons such as emotional, mental or physical illness, deficiency, or disability.
|
6.
|
Foreign Entities
. Without regard to the circumstances of Executive's termination from employment, Executive hereby also covenants that upon termination, if she/he is listed as an officer, director, partner, secretary or shareholder on any corporation, subsidiary or branch on behalf of Nature's Sunshine Products, Inc. or any related entity, he/she will sign over any and all rights to stock and/or resign as an officer or
|
6.
|
Restrictive Covenants. In recognition of the compensation and other benefits provided to Executive pursuant to this Agreement, Executive agrees to be bound by the provisions of this Section (the "Restrictive Covenants"). These Restrictive Covenants will apply without regard to whether any termination or cessation of Executive's employment is initiated by the Company or Executive, and without regard to the reason for that termination or cessation.
|
1.
|
Covenant Not To Compete
. Executive covenants that, during his employment by the Company and for a period of twelve (12) months following immediately thereafter, (the "Restricted Period"), Executive will not do any of the following, directly or indirectly:
|
1.
|
engage, be employed by, participate in, plan for or organize any Competing Business of the Company or any subsidiary or joint venture of the Company; "Competing Business" means any business enterprise that distributes through a multilevel marketing program or that engages in any activity that competes anywhere in the world with any activity in which the Company is then engaged, including sales or distribution of herbs, vitamins or nutritional supplements or any product, which the Company sells or distributes at the time of Executive's termination;
|
2.
|
become interested in (as owner, stockholder, lender, partner, coventurer, director, officer, employee, agent or consultant) any person, firm, corporation, association or other entity engaged in a Competing Business. Notwithstanding the foregoing, Executive may hold up to 2% of the outstanding securities of any class of any publicly-traded securities of any company;
|
3.
|
influence or attempt to influence any employee, sales leader, manager, coordinator, consultant, supplier, licensor, licensee, contractor, agent, strategic partner, distributor, customer or other person to terminate his or her employment with the Company or modify any written or oral agreement, relationship, arrangement or course of dealing the Company; or
|
4.
|
solicit for employment or employ or retain (or arrange to have any other person or entity employ or retain) any person who has been employed or retained by any member of the Company within the preceding twelve (12) months. For this purpose, advertisements for employment placed in newspapers of general circulation will not be considered solicitation.
|
5.
|
Extension of Restrictive Covenants
. The Company may elect to extend the twelve (12) month post-termination non-compete and non-solicitation period by up to twelve (12) additional months by delivering written notice of such extension to Executive at least thirty (30) days prior to the end of that twelve (12) month period and by making monthly payments to Executive for the number of months equal to the length of the extension specified by the Company in its notice to the Executive. The amount of each such additional monthly payment will be equal to one-twelfth of the base salary in effect at the time of Executive's termination of employment.
|
2.
|
Confidentialitv
. Executive recognizes and acknowledges that the Proprietary Information (as defined below) is a valuable, special and unique asset of the business of the Company. As a result, both during the Term and thereafter, Executive will not, without the prior written consent of the Company, for any reason divulge to any third-party or use for his/her own benefit. or for any purpose other than the exclusive benefit of the Company, any Proprietary Information. Notwithstanding the foregoing, if Executive is compelled to disclose Proprietary Information by court order or other legal process, to the extent permitted by applicable law, he shall promptly so notify the Company so that it may seek a protective order or other assurance that confidential treatment of such Proprietary Information shall be afforded, and Executive shall reasonably cooperate with the Company in connection therewith. If Executive is so obligated by court order or other legal process to disclose Proprietary Information, Executive will disclose only the minimum amount of such Proprietary Information as is necessary for Executive to comply with such court order or other legal process.
|
3.
|
Property of the Company
.
|
1.
|
Proprietary Information.
All right, title and interest in and to Proprietary Information will be and remain the sole and exclusive property of the Company. Executive will not remove from the Company's offices or premises any documents, records, notebooks, files, correspondence, reports, memoranda or similar materials of or containing Proprietary Information, or other materials or property of any kind belonging to the Company unless necessary or appropriate in the performance of his duties to the Company. If Executive removes such materials or property in the performance of his duties, he will return such materials or property promptly after the removal has served its purpose. Executive will not make, retain, remove and/or distribute any copies of any such materials or property, or divulge to any third person the nature of and/or contents of such materials' or property, except to the extent necessary to perfórm his/her duties on behalf of the Company. Upon termination of Executive's employment with the Company, s/he will leave with the Company or promptly return to the Company all originals and copies of such materials or property then in his/her possession.
|
a)
|
"Proprietary Information" means any and all proprietary information developed or acquired by the Company that has not been specifically authorized to be disclosed. Such Proprietary Information shall include, but shall not be limited to, the following items and information relating to the following items: (a) all trade secrets (including research and development, know-how, formulas, compositions, manufacturing and production processes and techniques, methodologies, technical data, designs, drawings and specifications) as well as all inventions (whether patentable or unpatentable and whether or not reduced to practice) and all improvements thereto, (b) computer codes and instructions, processing systems and techniques, inputs, and outputs (regardless of the media on which stored or located) and hardware and software configurations, designs, architecture and interfaces, (c) business research, studies, procedures and costs, (d) financial data, (e) distributor network information, the identities of actual and prospective distributors and distribution methods, (f) marketing data, methods, plans and efforts, (g) the identities of actual and prospective suppliers, (h) the terms of contracts and agreements with, the needs and requirements of and the Company's course of dealing with, actual or prospective suppliers, (i) personnel information, (j) customer and vendor credit information, and (k) information received from third parties subject to obligations of nondisclosure or non-use. Failure by the Company to mark any of the Proprietary Information as confidential or proprietary shall not affect its status as Proprietary Information.
|
2.
|
Intellectual Property
. Executive agrees that all the Intellectual Property (as defined below) will be considered "works made for hire' as that term is defined in Section 101 of the Copyright Act (17 U.S.C. § 101) and that all right, title and interest in such Intellectual Property will be the sole and exclusive property of the Company. To the extent that any of the Intellectual Property may not by law be considered a work made for hire, or to the extent that, notwithstanding the foregoing, Executive retains any interest in the Intellectual Property, Executive hereby irrevocably assigns and transfers to the Company any and all right, title, or interest that Executive may now or in the future have in the Intellectual Property under patent, copyright, trade secret, trademark or other law, in perpetuity or for the longest period otherwise permitted by law, without the necessity of further consideration. The Company will be entitled to obtain and hold in its own name all copyrights, patents, trade secrets, trademarks and other similar registrations with respect to such Intellectual Property. Executive further agrees to execute any and all documents and provide any further cooperation or assistance reasonably required by the Company to perfect, maintain or otherwise protect its rights in the Intellectual Property, at no cost to Executive. If the Company is unable after reasonable efforts to secure Executive's signature, cooperation or assistance in accordance with the preceding sentence, whether because of Executive's incapacity or any other reason whatsoever, Executive hereby designates and appoints the Company or its designee as Executive's agent and attorney-in-fact to act on his behalf solely for the purpose of executing and filing documents and doing all other lawfully permitted acts necessary or desirable to perfect, maintain or otherwise protect the Company's rights in the Intellectual Property. Executive acknowledges and agrees that such appointment is coupled with an interest and is therefore irrevocable.
|
a)
|
"Intellectual Property" means (a) all inventions (whether patentable or unpatentable and whether or not reduced to practice), all improvements thereto, and all patents and patent applications
|
4.
|
Acknowledgements
.
Executive acknowledges that the Restrictive Covenants are reasonable and necessary to protect the legitimate interests of the Company, that the duration and geographic scope of the Restrictive Covenants are reasonable given the nature of this Agreement and the position Executive holds within the Company, and that the Company would not enter into this Agreement or otherwise employ or continue to employ Executive unless Executive agrees to be bound by the Restrictive Covenants set forth in this
Section 6
.
|
5.
|
Remedies and Enforcement Upon Breach
.
|
1.
|
Intention
. It is the intention of the parties that the foregoing restrictive covenant be enforced as written, and, in any other event, enforced to the greatest extent (but to no greater extent) in time, territory and degree of participation as permitted by applicable law. Accordingly, in the event that any court to which a dispute over these restrictions may be referred shall find any of these restrictions overly broad or unreasonable in any way, that court must enforce the restrictions to the greatest extent deemed reasonable.
|
2.
|
Specific Enforcement
. Executive acknowledges that any breach by him, willfully or otherwise, of the Restrictive Covenants will cause continuing and irreparable injury to the Company for which monetary damages would not be an adequate remedy. In the event of any such breach or threatened breach by Executive of any of the Restrictive Covenants, the Company shall be entitled to injunctive or other similar equitable relief in any court, without any requirement that a bond or other security be posted, and this Agreement shall not in any way limit remedies of law or in equity otherwise available to the Company.
|
3.
|
Enforceability
. If any court holds the Restrictive Covenants unenforceable by reason of their breadth or scope or otherwise, it is the intention of the parties hereto that such determination not bar or in any way affect the right of the Company to the relief provided above in the courts of any other jurisdiction within the geographic scope of such Restrictive Covenants.
|
4.
|
Disclosure of
Restrictive Covenants
. Executive agrees to disclose the existence and terms of the Restrictive Covenants to any employer that Executive may work for during the Restricted Period.
|
5.
|
Extension of
Restricted Period
. If the Executive breaches
Section
6.1 in any respect, the restrictions contained in that section will be extended for a period equal to the period that the Executive was in breach.
|
7.
|
Miscellaneous.
|
1.
|
Other Agreements
. Executive represents and warrants to the Company that there are no restrictions, agreements or understandings whatsoever to which Executive is a party that would prevent or make unlawful his/her execution of this Agreement, that would be inconsistent or in conflict with this Agreement or Executive's obligations hereunder, or that would otherwise prevent, limit or impair the performance of Executive's duties under this Agreement.
|
2.
|
Successors and Assigns
. This Agreement shall be binding upon any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business and/or assets of the Company, and the Company shall require any such successor to expressly assume and agree in writing to perform this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such succession had taken place, or, in the event the Company remains in existence, the Company shall continue to employ Executive under the terms hereof. As used in this Agreement, the "
Company
" shall mean the Company and any successor to its business and/or assets, which assumes or is obligated to perform this Agreement by contract, operation of law or otherwise. This Agreement shall inure to the benefit of and be enforceable by Executive and his personal or legal representatives, executors, estate, trustee, administrators, successors, heirs, distributees. devisees and legatees. The duties of Executive hereunder are personal to Executive and may not be assigned by him. If Executive dies and any amounts become payable under this Agreement, the Company will pay those amounts to his estate.
|
3.
|
Governing Law and Enforcement: Disputes
. This Agreement shall be governed by and construed in accordance with the laws of the State of Utah, without regard to the principles of conflicts of laws. Any legal proceeding arising out of or relating to this Agreement will be instituted in a state or federal court in the State of Utah, and Executive and the Company hereby consent to the personal and exclusive jurisdiction of such court(s) and hereby waive any objection(s) that they may have to personal jurisdiction, the laying of venue of any such proceeding and any claim or defense of inconvenient forum.
|
4.
|
Waivers
. The waiver by either party of any right hereunder or of any breach by the other party will not be deemed a waiver of any other right hereunder or of any other breach by the other party. No waiver will be deemed to have occurred unless set forth in writing. No waiver will constitute a continuing waiver unless specifically stated, and any waiver will operate only as to the specific term or condition waived.
|
5.
|
Severability
. Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law. However, if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability will not affect any other provision, and this Agreement will be reformed, construed and enforced as though the invalid, illegal or unenforceable provision had never been herein contained.
|
6.
|
Survival.
Section 6
of this Agreement will survive termination of this Agreement and/or the cessation of Executive's employment by the Company.
|
7.
|
Notices
. Any notice or communication required or permitted under this Agreement shall be made in writing and shall be sufficient if personally delivered or sent by registered or certified mail and addressed, if to Employee, to Employee's address set forth in NSP's records, or if to NSP, to its principal office, to the attention of the CEO. Such notice shall be deemed given when delivered if delivered personally, or, if sent by registered or certified mail, at the earlier of actual receipt or three days after mailing in United States mail, addressed as aforesaid with postage prepaid.
|
8.
|
Entire Agreement: Amendments
. This Agreement, the attached exhibits, the Plan, and the Award Agreement contain the entire agreement and understanding of the parties hereto relating to the subject matter hereof; and merge and supersede all prior and contemporaneous discussions, agreements and understandings of every nature relating to Executive's employment or engagement with, or compensation by, the Company and any of its affiliates or subsidiaries or any of their predecessors, including, without limitation, the Existing Agreement. This Agreement may not be changed or modified, except by an agreement in writing signed by each of the parties hereto.
|
9.
|
Withholding
. All payments to Executive will be subject to tax withholding in accordance with applicable law.
|
10.
|
Section Headings
. The headings of sections and paragraphs of this Agreement are inserted for convenience only and shall not in any way affect the meaning or construction of any provision of this Agreement.
|
11.
|
Counterparts: Facsimile
. This Agreement may be executed in multiple counterparts (including by facsimile signature), each of which will be deemed to be an original, but all of which together will constitute one and the same instrument.
|
12.
|
Third Party Beneficiaries.
Subject to
Section 7.2
this Agreement will be binding on, inure to the benefit of and be enforceable by the parties and their respective heirs, personal representatives, successors and assigns. This Agreement does not confer any rights, remedies, obligations or liabilities to any entity or person other than Executive and the Company and Executive's and the Company's permitted successors and assigns, although this Agreement will inure to the benefit of the Company.
|
Employee:
|
Employer:
|
BRYANT J. YATES
|
NATURE’S SUNSHINE PRODUCTS, INC.
|
8.
|
Consideration. Executive acknowledges that: (i) the payments, rights and benefits set forth in Section 5 of the Agreement constitute full settlement of all his/her rights under the Agreement, and (ii) except as otherwise provided specifically in this Release. the Company does not and will not have any other liability or obligation to Executive under the Agreement. Executive further acknowledges that, in the absence of his execution of this Release. the benefits and payments specified in the Agreement (other than those specified) would not otherwise be due to him/her.
|
9.
|
Release and Covenant Not to Sue.
|
1.
|
Executive and the Company each hereby fully and forever releases and discharges the other, and all of their respective predecessors and successors, assigns, stockholders, subsidiaries, parents, affiliates, officers, directors, trustees, employees, agents and attorneys, past and present and in their respective capacities as such (the Company and Executive and each such respective person or entity is each referred to as a "
Released Person
") from any and all claims, demands, liens, agreements, contracts, covenants, actions, suits, causes of action, obligations, controversies, debts, costs, expenses, damages, judgments, orders and liabilities, of whatever kind or nature, direct or indirect, in law, equity or otherwise, whether known or unknown, arising through the date of this Release, including those arising out of Executive's employment by the Company or the termination thereof, including, but not limited to, any claims for relief or causes of action under the Age Discrimination in Employment Act, 29 U.S.C. § 621 et seq., or any other federal, state or local statute, ordinance or regulation regarding discrimination in employment and any claims, demands or actions based upon alleged wrongful or retaliatory discharge or breach of contract under any state or federal law.
|
2.
|
Executive and the Company expressly represent that they have not filed a lawsuit or initiated any other administrative proceeding against a Released Person and that neither has assigned any claim against a Released Person. Executive and the Company each further promise not to initiate a lawsuit or to bring any other claim against the other or any Released Person arising out of or in any way related to Executive's employment by the Company or the termination of that employment. This Release will not prevent Executive from filing a charge with the Equal Employment Opportunity Commission (or similar state agency) or participating in any investigation conducted by the Equal Employment Opportunity Commission (or similar state agency);
provided, however
, that any claims by Executive for personal relief in connection with such a charge or investigation (such as reinstatement or monetary damages) would be barred. This Release shall not affect Executive's rights under the Age Discrimination in Employment Act or the Older Workers Benefit Protection Act to have a judicial determination of the validity of this release and waiver.
|
10.
|
Restrictive Covenants. Executive acknowledges that the restrictive covenants contained in Section 6 of the Agreement will survive the termination of his employment. Executive affirms that those restrictive covenants are reasonable and necessary to protect the legitimate interests of the Company, that he received adequate consideration in exchange for agreeing to those restrictions and that he will abide by those restrictions.
|
11.
|
Non-Disparagement. Neither Executive nor the Company will disparage the other or any of their respective Released Persons or otherwise take any action which could reasonably be expected to adversely affect the personal or professional reputation of the other or their respective Released Persons.
|
12.
|
|
13.
|
|
14.
|
|
15.
|
|
16.
|
|
17.
|
|
18.
|
|
19.
|
|
20.
|
|
21.
|
|
22.
|
|
23.
|
|
24.
|
|
25.
|
Cooperation. Executive further agrees that, subject to reimbursement of his reasonable expenses, he will cooperate fully with the Company and its counsel with respect to any matter (including litigation, investigations, or governmental proceedings) in which Executive was in anyway involved during his employment with the Company. Executive shall render such cooperation in a timely manner on reasonable notice from the Company.
|
26.
|
Rescission Right. Executive expressly acknowledges and recites that (a) he has read and understands the terms of this Release in its entirety, (b) he has entered into this Release knowingly and voluntarily, without any duress or coercion; (c) he has been advised orally and is hereby advised in writing to consult with an attorney with respect to this Release before signing it; (d) he was provided twenty-one (21) calendar days after receipt of the Release to consider its terms before signing it; (e) should he nevertheless elect to execute this Agreement sooner than 21 days after he has received it, he specifically and voluntarily waives the right to claim or allege that he has not been allowed by the Company or by any circumstances beyond his control to consider this Agreement for a full 21 days; and (t) he is provided seven (7) calendar days from the date of signing to terminate and revoke this Release. in which case this Release shall be unenforceable, null and void. Executive may revoke this Release during those seven (7) days by providing written notice of revocation to the Company at the address specified in Section 7.8 of the Agreement.
|
27.
|
Challenge. If Executive violates or challenges the enforceability of any provisions of the Restrictive Covenants or this Release, no further payments, rights or benefits under Section 5 of the Agreement will be due to Executive (except where such provision would be prohibited by applicable law, rule or regulation).
|
28.
|
Miscellaneous.
|
1.
|
No Admission of
Liability
. This Release is not to be construed as an admission of any violation of any federal, state or local statute, ordinance or regulation or of any duty owed by the Company to Executive. There have been no such violations, and the Company specifically denies any such violations.
|
2.
|
No Reinstatement
. Executive agrees that he will not without the consent of the Company apply for reinstatement with the Company or seek in any way to be reinstated, reemployed or hired by the Company in the future,
|
3.
|
Successors and Assigns
. This Release shall inure to the benefit of and be binding upon the Company and Executive and their respective successors, permitted assigns executors, administrators and heirs. Executive shall not may make any assignment of this Release or any interest herein, by operation of law or otherwise. The Company may assign this Release to any successor to all or substantially all of its assets and business by means of liquidation, dissolution, merger, consolidation, transfer of assets, or otherwise.
|
4.
|
|
5.
|
Severability
. Whenever possible, each provision of this Release will be interpreted in such manner as to be effective and valid under applicable law. However, if any provision of this Release is held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability will not affect any other provision, and this Release will be reformed, construed and enforced as though the invalid, illegal or unenforceable provision had never been herein contained.
|
6.
|
Entire Agreement: Amendments
. Except as otherwise provided herein, this Release contains the entire agreement and understanding of the parties hereto relating to the subject matter hereof, and merges and supersedes all prior and contemporaneous discussions, agreements and understandings of every nature relating to the subject matter hereof This Release may not be changed or modified, except by an agreement in writing signed by each of the parties hereto.
|
7.
|
Governing Law
. This Release shall be governed by, and enforced in accordance with, the laws of the State of Utah, without regard to the application of the principles of conflicts of laws.
|
8.
|
Counterparts and Facsimiles
. This Release may be executed, including execution by facsimile signature, in multiple counterparts, each of which shall be deemed an original, and all of which together shall be deemed to be one and the same instrument.
|
Employee:
|
Employer:
|
BRYANT J. YATES
|
NATURE’S SUNSHINE PRODUCTS, INC.
|
29.
|
Section 4 shall be amended by adding the following at the end thereof:
|
30.
|
Section 5.1.3 shall be amended by adding the following at the end thereof:
|
31.
|
The last sentence of Section 5.5 shall be replaced with the following:
|
BRYANT J. YATES
|
|
Subsidiary
|
|
Jurisdiction
|
Nature's Sunshine Products of Canada, Ltd.
|
|
Canada
|
Nature's Sunshine Products de Mexico, S.A. de C.V.
|
|
Mexico
|
Nature's Sunshine Products de Colombia, S.A.
|
|
Colombia
|
Nature's Sunshine Produtos Naturais Ltda.
|
|
Brazil
|
Nature’s Sunshine Marketing Ltda.
|
|
Brazil
|
Nature's Sunshine Products de Venezuela, C.A.
|
|
Venezuela
|
NSP de Centroamérica, S.A
|
|
Costa Rica
|
Nature’s Sunshine Products de Panamá, S.A.
|
|
Panama
|
NSP de Guatemala, S.A.
|
|
Guatemala
|
Nature’s Sunshine Products de El Salvador, S.A. de C.V.
|
|
El Salvador
|
Nature’s Sunshine Products del Ecuador, S.A.
|
|
Ecuador
|
Nature’s Sunshine Products de Honduras, S.A. de C.V.
|
|
Honduras
|
Nature’s Sunshine Products de Nicaragua, S.A.
|
|
Nicaragua
|
Nature's Sunshine Products (Israel) Ltd.
|
|
Israel
|
Nature’s Sunshine Products of Russia, Inc.
|
|
Utah
|
Nature’s Sunshine Products Poland sp. z.o.o.
|
|
Poland
|
Nature’s Sunshine Products Dominicana, S. R.L.
|
|
Dominican Republic
|
Nature’s Sunshine Products International Distribution B.V.
|
|
Netherlands
|
NSP International Holdings C.V.
|
|
Netherlands
|
Quality Nutrition International, Inc.
|
|
Utah
|
Synergy Taiwan, Inc.
|
|
Utah
|
Synergy Worldwide Inc.
|
|
Utah
|
Synergy Worldwide Marketing (Thailand) Ltd.
|
|
Thailand
|
Synergy Worldwide Australia PTY Ltd.
|
|
Australia
|
Synergy Worldwide Canada B.V.
|
|
Netherlands
|
Synergy Worldwide Distribution Canada, ULC
|
|
Canada
|
Synergy Worldwide Italy S.R.L.
|
|
Italy
|
Synergy Worldwide Korea Ltd.
|
|
Korea
|
Synergy Worldwide Japan G.K.
|
|
Japan
|
Synergy Worldwide (S) PTE Ltd.
|
|
Singapore
|
Synergy Worldwide Nutrition Israel Ltd.
|
|
Israel
|
Synergy Worldwide (HK) Ltd.
|
|
Hong Kong
|
PT Nature’s Sunshine Products Indonesia
|
|
Indonesia
|
NATR Distribution (M) SDN. BHD.
|
|
Malaysia
|
Synergy WorldWide Europe B.V.
|
|
Netherlands
|
Synergy Worldwide Europe Management Services B.V.
|
|
Netherlands
|
Synergy WorldWide New Zealand B.V.
|
|
Netherlands
|
Synergy Worldwide New Zealand
|
|
New Zealand
|
Synergy WorldWide Philippines Distribution, Inc.
|
|
Philippines
|
Synergy Vietnam Co., Ltd.
|
|
Vietnam
|
Synergy WorldWide Marketing (M) SDN BHD.
|
|
Malaysia
|
Nature’s Sunshine (Far East) Limited
|
|
Hong Kong
|
Shanghai Nature’s Sunshine Health Products Trading Co. Ltd.
|
|
China
|
Nature’s Sunshine Hong Kong Limited
|
|
Hong Kong
|
Synergy WorldWide Nutrition Products (Hong Kong)
|
|
Hong Kong
|
Synergy WorldWide, Inc. (Philippines)
|
|
Philippines
|
PT Synergy WorldWide Indonesia
|
|
Indonesia
|
Synergy Worldwide Europe Management Services Spain S.L.U.
|
|
Spain
|
Synergy Worldwide Switzerland GmbH
|
|
Switzerland
|
/s/ Deloitte & Touche LLP
|
|
|
|
Salt Lake City, Utah
|
|
March 16, 2018
|
|
1.
|
I have reviewed this Annual Report on Form 10-K for the year ended
December 31, 2017
of Nature’s Sunshine Products, Inc. (the “registrant”);
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4.
|
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
(a)
|
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
(b)
|
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
(c)
|
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
(d)
|
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
5.
|
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
|
(a)
|
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
|
(b)
|
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
|
/s/ Gregory L. Probert
|
|
|
Chief Executive Officer and Chairman of the Board
|
|
|
March 16, 2018
|
|
1.
|
I have reviewed this Annual Report on Form 10-K for the year ended
December 31, 2017
of Nature’s Sunshine Products, Inc. (the “registrant”);
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4.
|
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
(a)
|
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
(b)
|
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
(c)
|
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
(d)
|
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
5.
|
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
|
(a)
|
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
|
(b)
|
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
|
/s/ Joseph W. Baty
|
|
|
Executive Vice President, Chief Financial Officer and Treasurer
|
|
|
March 16, 2018
|
|
1.
|
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
|
2.
|
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the periods presented in the Report.
|
|
/s/ Gregory L. Probert
|
|
|
Gregory L. Probert
|
|
|
Chief Executive Officer and Chairman of the Board
|
|
|
March 16, 2018
|
|
1.
|
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
|
2.
|
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the periods presented in the Report.
|
|
/s/ Joseph W. Baty
|
|
|
Joseph W. Baty
|
|
|
Executive Vice President, Chief Financial Officer and Treasurer
|
|
|
March 16, 2018
|
|